Finex logo
Finex Intelligence

Market Signal Briefing

Real-time pulse of financial headlines curated from 2 premium feeds.

Last news saved at Mar 12, 04:37 52m ago Cron last ran Mar 12, 04:37 53m ago 2 sources live
Switch language
82,518 Stories ingested Auto-fetched market intel nonstop.
400 Distinct tickers Symbols referenced across the feed
stockne... Trending sources stocknewsapi • cryptonews
Hot tickers
BTC XRP ETH BNO DBO GUSH
Surfacing from current coverage
Details Saved Published Title Source Tickers
2026-03-05 20:06 6d ago
2026-03-05 14:42 6d ago
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease stocknewsapi
QURE
UniQure needs to run another study to prove that its gene therapy "actually helps people with Huntington's disease," a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn't ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

"So what is really going on? UniQure is the latest company to make a failed therapy for Huntington's patients," the official said. "They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA."

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC's Becky Quick last week seemingly criticized UniQure's gene therapy for Huntington's disease. Makary didn't name UniQure but described its treatment.

watch now

UniQure then accused the FDA of reversing its stance that the company's clinical trial data would be sufficient to seek approval. UniQure's study used an outside database to measure how patients with Huntington's disease might decline without treatment, known as an external control. UniQure has said it wouldn't be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn't be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency "never agreed to accept this distorted comparison" and the FDA "never makes such assurances." Instead, the "FDA will always say, 'Well, we have to see the data when we get it.'"

UniQure didn't immediately comment.

The company's stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
2026-03-05 20:06 6d ago
2026-03-05 14:45 6d ago
CRWV 8-DAY DEADLINE ALERT: Hagens Berman Analyzes CoreWeave (CRWV) $452M Q4 Loss and Soft Guidance Amid Ongoing Securities Fraud Litigation stocknewsapi
CRWV
Q4 Net Loss Nearly Doubles Estimates; Firm Reminds Investors of March 13 Lead Plaintiff Deadline

, /PRNewswire/ -- National shareholder rights law firm Hagens Berman provides an update to investors in CoreWeave, Inc. (NASDAQ: CRWV) following the company's dismal fourth-quarter 2025 financial results. The news follows allegations that the company concealed operational failures, as pled in a recently filed securities class action.

Hagens Berman is investigating the alleged claims in the pending suit. The firm urges investors who suffered substantial losses to:

SUBMIT YOUR LOSSES NOW

On February 26, 2026, CoreWeave reported a Q4 net loss of $452 million, or $0.89 per share—a staggering figure that nearly doubled the $0.49 loss per share anticipated by Wall Street analysts. Compounding the miss, CoreWeave issued a soft Q1 2026 revenue guidance of $1.9 billion to $2.0 billion, falling significantly short of the $2.3 billion consensus. On this news, CRWV shares plunged nearly 20%.

The disappointing Q4 results come after the filing of a securities class action suit against CoreWeave and certain of its executives arising from the company's inability to scale its high-performance computing (HPC) clusters at the pace allegedly promised.

"We are investigating whether the company overstated scaling capabilities and hid critical delays," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims.

View our latest video summary of the allegations: youtube.com/watch?v=rWaDX1uGyJs

The CoreWeave, Inc. (CRWV) Securities Class Action

The pending securities class action, Masaitis v. CoreWeave, Inc., et al., No. 2:26-cv-00355, filed in the U.S. District Court for the District of New Jersey, seeks to recover losses for investors who acquired CoreWeave securities between March 28, 2025, and December 15, 2025 (the "Class Period").

The complaint alleges that CoreWeave and its executives violated the Securities Exchange Act of 1934 by:

Overstating Scaling Capabilities: Allegedly misrepresenting the company's ability to satisfy "unprecedented" demand for its NVIDIA-powered AI cloud. Concealing Critical Delays: Failing to disclose that the Denton, Texas data center cluster—intended to service OpenAI—was months behind schedule due to weather and design plan revisions. Single-Supplier Dependency: Understating the operational and financial risks of its heavy reliance on a single third-party data center developer. Share Price Erosion: Since these infrastructure failures began to surface in late 2025, CoreWeave's stock has faced severe downward pressure, further exacerbated by the latest Q4 earnings shock. Critical Deadline: March 13, 2026

If you purchased CoreWeave common stock during the Class Period (Mar. 28, 2025 – Dec. 15, 2025) and suffered substantial losses, you have until March 13, 2026, to ask the Court to appoint you as Lead Plaintiff.

TO SUBMIT YOUR COREWEAVE (CRWV) INVESTMENT LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:

Report your CRWV Investment Losses to Hagens Berman Now If you'd like more information and answers to frequently asked questions about the CoreWeave case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding CoreWeave should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP
2026-03-05 20:06 6d ago
2026-03-05 14:45 6d ago
5 Best Dividend Stocks To Combine Growth, Income, And Defense In 2026 stocknewsapi
DELL LMT NEM PINE PM
HomeStock IdeasQuick Picks & Lists

SummaryPeriods of persistent inflation, higher interest rates, and geopolitical tension can create a challenging environment for investors.Companies that can provide a defensive and diversified mix in this macro backdrop, including hard assets, resilient consumer demand, income-generating real estate, and tech infrastructure.By combining reliable dividends backed by outstanding profitability, five companies illustrate how investors can build portfolios that can withstand volatility while maintaining exposure to potential upside in 2026.I am Steven Cress, Head of Quantitative Strategies at Seeking Alpha. I manage the quant ratings and factor grades on stocks and ETFs in Seeking Alpha Premium. I also lead Alpha Picks, which selects the two most attractive stocks to buy each month, and also determines when to sell them. Olivier Le Moal/iStock via Getty Images

Dividend Stocks That Can Thrive in a Challenging 2026 Macro Backdrop Investors entered 2026 expecting inflation to moderate, interest rates to gradually fall, and geopolitical tensions to remain modestly high but contained. However, reality has presented a more challenging set of circumstances. A resilient labor

87.38K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. Steven Cress is the Head of Quantitative Strategy at Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
2026-03-05 20:06 6d ago
2026-03-05 14:45 6d ago
Ituran Location and Control Ltd. (ITRN) Q4 2025 Earnings Call Transcript stocknewsapi
ITRN
Ituran Location and Control Ltd. (ITRN) Q4 2025 Earnings Call Transcript
2026-03-05 20:06 6d ago
2026-03-05 14:45 6d ago
Permanent TSB Group Holdings plc (ILPMY) Q4 2025 Earnings Call Transcript stocknewsapi
ILPMY
Permanent TSB Group Holdings plc (ILPMY) Q4 2025 Earnings Call Transcript
2026-03-05 20:06 6d ago
2026-03-05 14:46 6d ago
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript stocknewsapi
VMD
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript
2026-03-05 20:06 6d ago
2026-03-05 14:46 6d ago
Varonis Systems, Inc. (VRNS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript stocknewsapi
VRNS
Varonis Systems, Inc. (VRNS) Morgan Stanley Technology, Media & Telecom Conference 2026 March 5, 2026 12:15 PM EST

Company Participants

Brian Vecci - Field C.T.O
Guy Melamed - CFO & COO

Conference Call Participants

Meta Marshall - Morgan Stanley, Research Division

Presentation

Meta Marshall
Morgan Stanley, Research Division

All right. Welcome, everybody. While we get situated, I'll read the disclosures real quick. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

I'm Meta Marshall. I cover cybersecurity here at Morgan Stanley. We're delighted to have Varonis, Guy Melamed, CFO; Brian Vecci, CTO.

Question-and-Answer Session

Meta Marshall
Morgan Stanley, Research Division

All right. Perfect. Maybe just to kind of start with in terms of -- just those who are kind of less familiar with Varonis or kind of data security in general, just kind of giving an overview of the company.

Brian Vecci
Field C.T.O

So where I'd start is almost all aspects of cybersecurity touches on data. Nobody breaks into a bank to steal the pens, they're after money. Nobody gets access to an account, an identity, an API these days, an agent, your infrastructure unless they're really after data. Companies face when it comes to data because they have so much not just in data centers these days, but in various cloud platforms, all of the hyperscalers, the applications, all of the AI workloads that they're building. They face a lot of regulatory risk. What do I have? Where is it? Are all the right controls in place, a lot of reputational risk. They don't want to be on the front page of the Wall Street Journal because they got breached.

And they need to do more with less. They need to
2026-03-05 20:06 6d ago
2026-03-05 14:46 6d ago
Ellington Credit Company (EARN) Q4 2025 Earnings Call Transcript stocknewsapi
EARN
Ellington Credit Company (EARN) Q4 2025 Earnings Call Transcript
2026-03-05 20:06 6d ago
2026-03-05 14:46 6d ago
Endeavour Mining plc (EDV:CA) Q4 2025 Earnings Call Transcript stocknewsapi
EDV EDVMF
Q4: 2026-03-05 Earnings SummaryEPS of $1.27 beats by $0.09

 |

Revenue of

$1.74B

(28.39% Y/Y)

beats by $69.23M

Endeavour Mining plc (EDV:CA) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST

Company Participants

Jack Garman - Vice President of Investor Relations
Ian Cockerill - CEO & Executive Director
Guy Young - Executive VP & CFO
Djaria Traore - Executive Vice President of Operations & ESG

Conference Call Participants

Alain Gabriel - Morgan Stanley, Research Division
Ovais Habib - Scotiabank Global Banking and Markets, Research Division
Fahad Tariq - Jefferies LLC, Research Division
Marina Calero Ródenas - RBC Capital Markets, Research Division
Frederic Bolton - BMO Capital Markets Equity Research
Mohamed Sidibe - National Bank Financial, Inc., Research Division
Daniel Major - UBS Investment Bank, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to Endeavour Mining's Fourth Quarter and Full Year 2025 Results Webcast. [Operator Instructions] Today's conference call is being recorded, and a transcript of the call will be available on Endeavour's website tomorrow.

I would now like to hand the call over to Endeavour's Vice President of Investor Relations, Jack Garman. Please go ahead.

Jack Garman
Vice President of Investor Relations

Hello, everyone, and welcome to Endeavour's Q4 and Full Year 2025 Results Webcast.

Before we start, please note our usual disclaimer. On the call today, I'm delighted to be joined by Ian Cockerill, Chief Executive Officer; Guy Young, Chief Financial Officer; and Djaria Traore, Executive Vice President of Operations and ESG.

Today's call will follow our usual format. Ian will first go through the highlights of the quarter and the year, Guy will present the financials, and Djaria will walk through our operating results by mine before handing back to Ian for his closing remarks. We'll then open the line up for questions.

With that, I'll now hand over to Ian.

Ian Cockerill
CEO & Executive Director

Thank you, Jack, and hello to everyone who's joining us on the
2026-03-05 20:06 6d ago
2026-03-05 14:46 6d ago
GitLab Inc. (GTLB) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript stocknewsapi
GTLB
GitLab Inc. (GTLB) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
2026-03-05 20:06 6d ago
2026-03-05 14:49 6d ago
Coda Octopus Group Sets Fiscal First Quarter 2026 Earnings Conference Call for Tuesday, March 17, 2026, at 10 a.m. Eastern Time stocknewsapi
CODA
Orlando, FL, March 05, 2026 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology (“DAVD”), will host a conference call on Tuesday, March 17, 2026 at 10:00 a.m. Eastern time to discuss its results for its Fiscal First Quarter 2026 ended January 31, 2026 (“FQ2026”). A press release detailing these results will be issued before the opening of trading on March 17, 2026.

The Company’s management will provide prepared remarks, followed by a question-and-answer period.

Date: Tuesday, March 17, 2026
Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)
U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879
International number: 1-201-389-0879
Conference ID: 13758973

The conference call will broadcast live and be available for replay here.

Persons interested in attending are required to call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please press *0.

A replay of the call will be available after approximately 2:00 p.m. Eastern time on the same day through Tuesday, March 31, 2026 at 11:59 p.m. ET.

Telephone replay numbers: 1-844-512-2921 or 1-412-317-6671
International replay number: 1-412-317-6671
Access ID: 13758973

About Coda Octopus Group, Inc.

The Company, founded in 1994, is an established supplier to the underwater/subsea market. It supplies a range of hardware and software solutions which includes key proprietary real time 4D/5D/6D imaging sonars, marketed under the name Echoscope®, Echoscope PIPE® and Echoscope PIPE NANO Gen Series® addressing the underwater imaging sensor market along with new generation diving technology, known as the Diver Augmented Vision Display (“DAVD”) system. The Company’s Echoscope PIPE® sonar generates real-time 3D/4D/5D images of moving objects underwater including in zero visibility water conditions. Echoscope technology is used globally for numerous applications in both the commercial offshore market and defense underwater markets. Applications for the Echoscope® technology include complex mapping underwater, subsea intervention, subsea asset placements, salvage and recovery, search and rescue, offshore renewables cable installations and surveys, marine construction, subsea infrastructure installation, mining applications, robotics (3D Perception and Depth), breakwater construction and monitoring, decommissioning, diving applications and port and harbor security.

The recently launched new generation of diving technology, DAVD, has the potential to change the way global diving operations are performed (both in the Defense and Commercial space) because it is a fully integrated singular system for topside control and fully connected diver HUD system, allowing both the topside and diver to share a range of critical information and visualize the same underwater scene. Furthermore, the DAVD integrates the Company’s sonar technology, which allows dive operations to be performed in zero visibility conditions, a common problem that besets these operations.

The Company also includes two discrete Defense Engineering Services businesses Coda Octopus Martech Ltd (UK based) and Coda Octopus Engineering, Inc. (US based) whose primary business model is to supply sub-assemblies into broader mission critical programs in the capacity of sub-contractors to the Prime Defense Contractors. Their scope of supply under these programs typically includes concept, design, prototype, manufacturing, and post-sale support. This gives them the opportunity to have repeat orders for these sub-assemblies through the life of these programs.

The Company recently acquired Precision Acoustics Limited, an acoustics sensor and materials business. PAL is a supplier of acoustic sensors and materials. PAL also performs calibration services for medical devices and is accredited to ISO/IEC 17025 standard. PAL is one of only two organizations in the United Kingdom with this certification, alongside the National Physical Laboratory (NPL). Globally, only a handful of facilities hold ISO/IEC 17025 accreditation for these measurements. Ultrasonic free-field sensitivity calibration is critical for markets that require precision ultrasonic measurement, strict safety compliance, and full metrological traceability. These include regulated and high-risk applications, such as diagnostic and therapeutic medical ultrasound and defense and underwater acoustics, where free-field calibration is essential to ensure accurate beam sensitivity and minimal interference. PAL’s operations are based in the United Kingdom.

For further information, please visit http://www.codaoctopusgroup.com or contact us at [email protected].

Forward Looking Statements

This press release contains forward-looking statements concerning Coda Octopus Group, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “assume” and similar expressions are intended to identify forward‐looking statements. Those forward-looking statements include, without limitation, statements regarding the Company's expectations for the growth of the Company's operations and revenue. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, fluctuations in foreign exchange rates, changes in global economic condition, tariff and trade policies, reduction in government spending in the Defense Sector, customer demand, geopolitical issues, the outcome of our ongoing research and development efforts relating to our products including our patented real time 3D solutions or DAVD; our ability to develop the sales force required to achieve our development and other examples of forward looking statement set forth in our Annual Report on Form 10-K for the year ended October 31, 2025, filed with the Securities and Exchange Commission on January 29, 2026 as amended on our Form 10-K/A, filed with the Securities and Exchange Commission on February 26, 2026. Coda Octopus Group, Inc., does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:
Mr. Dillon King
Coda Octopus IR Team at [email protected]
Coda Octopus Group, Inc.
1- 407-735-2406
2026-03-05 20:06 6d ago
2026-03-05 14:49 6d ago
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Texas Mineral Resources Corp. (OTCQB: TMRC) stocknewsapi
TMRC
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Texas Mineral Resources Corp. (OTCQB: TMRC) related to its sale to USA Rare Earth, Inc. for 3,823,328 shares of USA Rare Earth common stock. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/texas-mineral-resources-corp/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC
2026-03-05 20:06 6d ago
2026-03-05 14:49 6d ago
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Farmer Brothers Co. (NASDAQ: FARM) stocknewsapi
FARM
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Farmer Brothers Co. (NASDAQ: FARM) related to its sale to Royal Cup, Inc. Under the terms of the proposed transaction, Farmer shareholders are expected to receive $1.29 per share in cash. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/farmer-brothers-co/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC
2026-03-05 20:06 6d ago
2026-03-05 14:49 6d ago
Suntex Enterprises Signs Letter of Intent to Acquire Deep South Electrical Contractors and GoldenEra Development from Golden Triangle Ventures stocknewsapi
SNTX
AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- via IBN – Suntex Enterprises, Inc. (OTC: SNTX) today announced that it has executed a Letter of Intent (LOI) to acquire Deep South Electrical Contractors and GoldenEra Development, two operating subsidiaries currently held by Golden Triangle Ventures, Inc.

The agreement outlines Suntex’s intent to bring both operating businesses under the Suntex corporate structure, further expanding the Company’s operating footprint across infrastructure, construction services, and development operations.

Deep South Electrical Contractors is an active commercial and industrial electrical contractor supporting large-scale infrastructure and technology-driven facilities. GoldenEra Development provides construction management and development services tied to commercial and industrial projects. Both businesses are currently operating and engaged on projects supporting continued growth.

Management believes the addition of these operating companies will significantly strengthen Suntex’s revenue base and expand its ability to pursue larger infrastructure and development opportunities.

“This agreement represents another step in building Suntex into a stronger operating company,” said Javier Leal, CEO of Suntex Enterprises. “Deep South Electrical Contractors and GoldenEra Development bring established operations and ongoing project activity. Bringing these businesses under the Suntex umbrella allows us to continue expanding our operational platform and scale.”

The execution of the Letter of Intent reflects the parties’ commitment to move forward with definitive agreements and finalize the transaction following customary due diligence and closing conditions.

Full terms of the transaction, including the structure of the acquisition, will be announced once definitive agreements are finalized.

About Suntex Enterprises, Inc.

Suntex Enterprises, Inc. (OTC: SNTX) is focused on building and acquiring operating businesses across infrastructure, construction services, and asset-backed development opportunities. The Company’s strategy centers on expanding revenue-generating operations while strengthening its operational foundation for long-term growth.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect current expectations regarding future events and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Suntex Enterprises undertakes no obligation to update forward-looking statements except as required by law.

MEDIA CONTACT
JA Development & Construction Media Relations
[email protected]

SOCIAL
X: @SuntexEnt25 | @JA_Development

InvestorWire Service Contact:

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
2026-03-05 20:06 6d ago
2026-03-05 14:50 6d ago
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical stocknewsapi
TVGN
WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Apozeal Pharmaceutical Inc. (“Apozeal”), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines.

The proposed transaction represents a strategic step in advancing Tevogen Generics, established to support domestic pharmaceutical manufacturing and enhance affordability and national supply chain resilience.

If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including:

11 FDA-approved Abbreviated New Drug Application (ANDA) products for the U.S. marketMultiple ANDAs currently filed with the U.S. Food and Drug Administration awaiting approvalAdditional generic products in development Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “Tevogen Generics was launched with the objective of supporting pharmaceutical affordability and domestic manufacturing in the United States. The potential acquisition of Apozeal represents a meaningful step toward that strategy. With FDA-approved ANDA assets and a growing development pipeline, Apozeal could provide a foundation for building a revenue-generating generics business and could support Tevogen’s broader plan to expand U.S.-based pharmaceutical manufacturing.”

The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions.

Tevogen is also actively considering other transactions with a focus on life sciences-related businesses; however, there can be no assurance that any such transaction will be consummated.

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction with Apozeal and the potential benefits of the transaction; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction with Apozeal; the risk that the transaction with Apozeal may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction with Apozeal may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]
2026-03-05 20:06 6d ago
2026-03-05 14:53 6d ago
Buy the Dip on This Bank Stock, Says Long-Term Signal stocknewsapi
MS
$40 Gets You 4 High-Conviction Trades. Let's Go.

We just booked back-to-back double-digit gains on Celsius and Palantir in Trade of the Week, and we’re eyeing even bigger wins!

Every week starts with a fully defined options trade straight from the desk Schaeffer’s Senior V.P. of Research, Todd Salamone, backed by 30+ years of proven market experience and disciplined risk management.

Right now, you can get 4 total trades over the next 4 weeks for $40 – just $10 per trade.

👉 Sign Up Now to Receive Your First Trade!
2026-03-05 20:06 6d ago
2026-03-05 14:54 6d ago
$DSGR: Distribution Solutions Group Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm stocknewsapi
DSGR
BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Distribution Solutions Group, Inc. (Nasdaq: DSGR) for potential securities law violations. Investors who have lost money in their Distribution Solutions Group investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/dsgr. 

What is this all about?

Shares of Distribution Solutions Group fell over 25% on March 5, 2026, after the company reported Q4 2025 results. On their Q4 earnings call, CEO Bryan King stated that the company had “navigated challenging headwinds in 2025…including those driven by fluid tariffs.” However, when asked whether the company felt like it had its “arms around” tariffs just months earlier at a November 18, 2025, conference, CFO Ron Knutson responded: “Yes, yes, yes, we can. We can plan around it,” and added that “we [the company] feel like we've been in a pretty good place around the tariff side.” Block & Leviton is investigating.

Who is eligible?

Anyone who purchased Distribution Solutions Group common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.

Whistleblower?

If you have non-public information about Distribution Solutions Group, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected] 
2026-03-05 20:06 6d ago
2026-03-05 14:55 6d ago
Robbins LLP Urges KD Stockholders Who Lost Money Investing in Kyndryl Holdings, Inc. to Contact the Firm for Information About Leading the Class Action stocknewsapi
KD
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Kyndryl Holdings, Inc. (NYSE: KD) securities between August 7, 2024 and February 9, 2026. Kyndryl describes itself as a “technology services company, which engages in the provision of infrastructure services.”

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is the class period? August 7, 2024 – February 9, 2026

What are the allegations? Robbins LLP is Investigating Allegations that Kyndryl Holdings, Inc. (KD) Materially Misstated its Financial Statements

According to the complaint, during the class period defendants failed to disclose that: (1) Kyndryl’s financial statements issued during the class period were materially misstated; (2) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; and (3) as a result, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.

Plaintiff alleges that on February 9, 2026, Kyndryl filed with the SEC a Notification of Late Filing on Form 12b-5 announcing it would be unable to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 within the necessary time. The late filing notice also revealed the existence of an investigation by the SEC into the Company’s financial reporting and that the Company's Chief Financial Officer and General Counsel departed their positions, and the Senior V.P. and Global Controller assumed a different role. On this news, Kyndryl’s stock price fell $12.90 per share, or 55%, to close at $10.59 on February 9, 2026.

What can shareholders do now? You may be eligible to participate in the class action against Kyndryl Holdings, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 13, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Kyndryl Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.
2026-03-05 20:06 6d ago
2026-03-05 14:55 6d ago
Impala Platinum Holdings Limited (IMPUY) Q2 2026 Earnings Call Transcript stocknewsapi
IMPUY
Impala Platinum Holdings Limited (IMPUY) Q2 2026 Earnings Call March 5, 2026 4:30 AM EST

Company Participants

Nicolaas Muller - CEO & Executive Director
Patrick Morutlwa - Group Chief Operating Officer
Meroonisha Kerber - CFO, Debt Officer & Executive Director
Johan Theron - Group Executive of Corporate Affairs
Adelle Coetzee
Moses Motlhageng - Chief Executive of Impala Rustenburg & CEO of Rustenburg Operations
Sifiso Sibiya - Group Executive of Refining & Marketing
Kirthanya Pillay - Group Executive of Corporate Development

Conference Call Participants

Christopher Nicholson - Morgan Stanley, Research Division
Gerhard Engelbrecht - Absa Bank Limited, Research Division
Arnold Van Graan - Nedbank Corporate and Investment Bank, Research Division
Nkateko Mathonsi - Investec Bank Limited (SA), Research Division

Presentation

Nicolaas Muller
CEO & Executive Director

Good morning to everyone. Welcome here to all those present, the investment community, our own Implats people and for everyone who's dialed in as well, welcome. Always an honor to represent a very talented Implats team. Extraordinary times that we are living in.

We had a presentation from one of the consulting firms the other day, and it was very clear that we are going through a shift in global order. It's a new era that is being introduced. We're seeing changes in international relationships, institutions, NATO, trade paths are changing, supply chains are changing. The move from globalization to multipolarity is accelerating. We just recently this weekend seen a new event unfold in the Middle East. And so all of this creates a number of consequences, one of which is uncertainty in future supply, particularly in natural resources and in our case, critical minerals and metals.

And critical can be defined in many ways. But one is, if it's used in critical industries like in Europe, the auto industry is a very important employer. It affects politics. And so without our metals, there is a risk for the industry. But
2026-03-05 20:06 6d ago
2026-03-05 14:55 6d ago
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript stocknewsapi
CRMD
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
2026-03-05 20:06 6d ago
2026-03-05 14:58 6d ago
Why Broadcom's earnings report has Wall Street so upbeat on a bad day for chip stocks stocknewsapi
AVGO
HomeIndustriesComputers/ElectronicsEarnings OutlookEarnings OutlookThe chip maker said it has visibility into more than $100 billion in AI chip revenue in 2027, and some analysts see even more upsidePublished: March 5, 2026 at 2:58 p.m. ET

Shares of Broadcom were climbing on Thursday, as investors looked to the company’s strong earnings report and upbeat outlook for its custom chip business to distract them from a broad selloff in the chip sector as well as in the overall stock market.

Broadcom AVGO CEO Hock Tan said during the post-earnings call with analysts late Wednesday there was a “line of sight” into more than $100 billion in revenue from its artificial-intelligence chips in 2027. The company’s custom AI chip ramps with its five major customers are “progressing very well,” Tan said. For the current quarter, Broadcom expects revenue to grow 140% over the previous year, to $10.7 billion.
2026-03-05 20:06 6d ago
2026-03-05 14:58 6d ago
US Proposes Rule Requiring Licenses for AI Chip Exports stocknewsapi
NVDA SMH SOXX
The US government drafted a rule requiring export licenses for AI chip shipments, including those from major companies like Nvidia and AMD, to all countries worldwide. Ed Ludlow has more on "Bloomberg Markets.
2026-03-05 19:06 6d ago
2026-03-05 13:50 6d ago
BD Gains FDA Clearance for Surgiphor 1000mL Surgical Irrigation System stocknewsapi
BDX
Key Takeaways BDX secured FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system.The ready-to-use sterile solution helps remove debris and microorganisms during wound irrigation in surgery.The new 1000mL format expands BD's Surgiphor portfolio with both manual and powered irrigation options. Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system. The product is the first antimicrobial irrigation solution available in a 1000mL format designed for powered lavage, providing a standardized and OR-ready option to support surgical safety and procedural performance. The Surgiphor 1000mL expands BD’s existing Surgiphor portfolio and enables clinicians to mechanically remove debris and microorganisms from wounds during powered irrigation procedures.

Per management, the FDA clearance further strengthens the company’s leadership in surgical irrigation technologies. The Surgiphor 1000mL antimicrobial irrigation system is designed to deliver consistent and safe irrigation performance, supporting surgical teams in improving procedural efficiency and patient care outcomes.

Likely Trend of BDX Stock Following the NewsShares of BDX have lost 1.6% since the announcement on Monday. Over the past six months, shares of the company declined 10.9% against the industry’s 23.3% growth and the S&P 500’s 6.4% rise.

In the long run, the FDA 510(k) clearance for BD’s Surgiphor 1000mL is expected to strengthen the company’s position in the wound irrigation systems market. By expanding the Surgiphor platform with a larger-volume powered irrigation option, the company can strengthen adoption across hospitals that rely on standardized, ready-to-use solutions to improve surgical outcomes and operational efficiency. The innovation also supports BDX’s broader strategy of expanding its surgery portfolio with integrated solutions that combine devices, consumables and clinical workflow support, which could help drive recurring product demand and strengthen hospital partnerships.

BDX currently has a market capitalization of $49.60 billion.

Image Source: Zacks Investment Research

More on the Surgiphor 1000mLThe Surgiphor 1000mL antimicrobial irrigation system is supplied as a ready-to-use sterile solution, eliminating the need for manual mixing by hospital staff. This design helps reduce preparation time in the operating room while supporting adherence to established safety standards for surgical wound irrigation. Building on the market adoption of the original Surgiphor antimicrobial irrigation system, the 1000mL configuration provides operating room teams with a higher-volume option designed to integrate with existing powered irrigation systems.

Engineered to work with widely used powered lavage devices, the system features a powered-device adapter along with a Y-connector that allows clinicians to switch between saline and Surgiphor solution during procedures. A twist cap is also included to support manual application when needed, providing additional flexibility for different clinical scenarios.

The design incorporates integrated venting to facilitate consistent and uninterrupted fluid flow, while the collapsible bottle structure helps ensure efficient evacuation and easier handling during use. The solution contains terminally sterile PVP-I (povidone-iodine) and forms part of BD’s broader surgical irrigation portfolio, offering terminally sterile PVP-I solutions in multiple volumes and delivery formats.

With the introduction of the 1000mL configuration, the Surgiphor antimicrobial irrigation system portfolio now includes both manual and powered irrigation options, allowing clinicians to choose formats that best align with procedural requirements and operating room workflows.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the wound irrigation systems market is valued at $356.16 million in 2026 and is expected to witness a CAGR of 4.7% through 2035.

Factors like the increasing chronic wound cases and the adoption of advanced, automated devices that improve infection control and healing efficacy are boosting the market’s growth.

Other NewsBD recently introduced the BD Vacutainer Urine Complete Cup Kit, a three-tube urine collection system aimed at expanding diagnostic testing from a single specimen. The launch highlights the company’s efforts to improve preanalytical workflows and laboratory efficiency. The kit is designed to preserve specimen integrity, reduce healthcare worker exposure and minimize repeat collections. Its unique third-tube configuration allows additional testing from one sample while eliminating manual transfers, thereby lowering contamination risks and improving operational safety in clinical environments.

In January, BD announced the commercial launch of BD Research Cloud 7.0, advancing its AI strategy in flow cytometry and life sciences research. The release features BD Horizon Panel Maker, an AI-driven tool that automates panel design — an essential step in immunology and oncology experiments to improve data quality and reliability. The cloud-based platform supports collaboration, workflow optimization and laboratory management.

BDX’s Zacks Rank & Key PicksCurrently, BDX carries a Zacks Rank #4 (Sell).

Some top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .

Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.

Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.
2026-03-05 19:06 6d ago
2026-03-05 13:50 6d ago
Roundhill's 50% Yield Innovation-100 ETF Is Waiting To Step on A Landmine stocknewsapi
QDTE
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Roundhill Innovation-100 0DTE Covered Call Strategy ETF (CBOE:QDTE) was built for a specific type of investor: someone who wants meaningful income from tech exposure without simply riding the Nasdaq up and down. The fund sells zero-days-to-expiration covered calls on the Innovation-100 Index each morning, collects the premium, and distributes it weekly. With roughly $927 million in assets and a strategy that has attracted a devoted income-seeking following, QDTE has delivered. But the architecture of the fund creates a specific landmine that most holders are not thinking about clearly.

The covered call premium cushions losses slightly on bad days. It does not stop them. And the holdings underneath this fund are not your average blue chips sitting quietly in a portfolio. They are some of the most volatile, highest-multiple, binary-outcome names in the market.

The Upside Cap Does Not Come With a Downside Floor The primary risk facing QDTE is straightforward but easy to underestimate: the fund’s underlying holdings can fall sharply, and the daily options premium collected does almost nothing to offset a serious drawdown. Selling a 0DTE covered call generates a small amount of daily income. It does not generate a hedge. If a core holding drops sharply in a week, a few days of premium income will not make a dent.

Strategy / MicroStrategy (MSTR) Consider what is actually sitting in this fund. Strategy (NASDAQ:MSTR), formerly MicroStrategy, is essentially a leveraged bitcoin vehicle. In Q4 2025, the company reported a net loss of $12.44 billion, driven almost entirely by a $17.44 billion unrealized loss on its bitcoin holdings. The company holds 713,502 bitcoins, and every meaningful move in bitcoin price flows directly into the stock. MSTR has already fallen 46.78% over the past year, and bitcoin itself has traded as low as $65,769 in early March 2026 after touching nearly its recent highs in late 2025. Polymarket traders currently price a 65.5% probability that bitcoin dips to $55,000 before year end. If that happens, MSTR would almost certainly crater, and QDTE’s daily call premium would be irrelevant noise against the NAV destruction.

Palantir (PLTR) Then there is Palantir (NASDAQ:PLTR | PLTR Price Prediction). The company posted genuinely strong Q4 2025 results, with revenue growing 70% year-over-year to $1.41 billion and a Rule of 40 score of 127%. But the stock trades at a trailing price-to-earnings ratio of around 234x and a price-to-sales ratio of nearly 79x. At that valuation, the margin for error is essentially zero. Any guidance miss, government contract reduction, or macro sentiment shift can trigger a violent repricing. Palantir’s own insiders have been selling aggressively, with CEO Alexander Karp and multiple other executives liquidating large positions on February 20, 2026, at prices between $132 and $136, well below where the stock had been trading just weeks earlier. Palantir is down 13.82% year-to-date through March 4.

Tesla (TSLA) Tesla (NASDAQ:TSLA) adds a different flavor of risk. Vehicle deliveries fell 16% year-over-year in Q4 2025 to 418,227 units, and automotive revenue declined 11%. The stock sits at a trailing P/E of 370x, which requires an enormous amount of future growth to justify. Kalshi prediction markets currently place only a 20% probability on Tesla delivering more than 500,000 vehicles in any single quarter before 2027, suggesting the crowd is skeptical of the exponential delivery growth the valuation demands. The stock is already down 9.73% year-to-date.

NVIDIA (NVDA) NVIDIA (NASDAQ:NVDA) is the fund’s most credible holding from a fundamental standpoint, with Q4 FY2026 revenue of $68.13 billion, up 73% year-over-year. But even NVIDIA carries a specific landmine: its Q1 FY2027 guidance explicitly excludes any Data Center compute revenue from China, a market where the company previously generated meaningful revenue. NVIDIA is down 6.4% over the past week as of March 4.

QDTE Fund Overview The transmission mechanism is simple. When any of these names gaps down sharply on a binary event, whether that is a bitcoin crash, a Palantir valuation reset, a Tesla delivery miss, or an escalation in China export restrictions, QDTE’s NAV drops with it. The daily premium from selling a covered call might represent a fraction of a percent of NAV. A significant drawdown in a major holding is not offset by a week’s worth of income distributions.

The Volatility Regime Can Work Against the Fund in Two Directions The secondary risk is subtler but equally real. QDTE’s income depends entirely on implied volatility in its underlying index. Higher volatility means fatter option premiums and bigger weekly distributions. Lower volatility means the opposite. The current environment creates a two-sided trap.

The VIX currently sits at 23.57, up 35.1% over the past month and sitting at roughly the 87th percentile of observations over the past year. That elevated reading is temporarily supportive of premium income. But it also reflects genuine market stress, which is precisely the environment where QDTE’s underlying holdings tend to suffer most. Innovation-oriented, high-multiple growth stocks are the first to be sold when fear rises.

The VIX reached a peak of 52.33 on April 8, 2025, during a period of extreme market panic. During that kind of event, QDTE would be collecting elevated premiums while simultaneously watching its NAV erode as holdings like MSTR, PLTR, and TSLA sold off hard. The premium income is procyclical with the fear that causes the damage.

If volatility instead normalizes back toward the 12-month average of around 19 or lower, premium income compresses and the fund’s headline yield shrinks. Investors who bought in for the distribution may find themselves holding a lower-yielding fund while the underlying holdings remain fully exposed to any future shock. The VIX touched 13.47 as recently as December 24, 2025, demonstrating how quickly the environment can shift.

What to Watch Before the Landmine Goes Off For the concentration and drawdown risk, the most actionable signal is bitcoin’s price. MSTR’s stock moves in tight correlation with bitcoin, and a break below the $65,769 support level seen on March 1 would likely accelerate selling pressure in MSTR and drag on QDTE’s NAV. Track bitcoin daily on any major exchange or financial data platform. The $60,000 level is the next meaningful floor to watch.

For Palantir specifically, monitor the company’s government contract pipeline. A meaningful reduction in U.S. government spending, or any high-profile contract termination, would hit a stock already priced for perfection. The company’s own SEC filings note that contracts are subject to termination for convenience provisions. Check Palantir’s quarterly filings for any changes in total contract value or government revenue trajectory.

For the volatility premium risk, the CBOE’s VIX index is the right instrument to monitor weekly. The critical threshold is sustained movement below 15, which historically signals a low-volatility regime where 0DTE premium income compresses significantly. The FRED VIX data series updates daily and provides the historical context needed to assess where current readings sit relative to recent norms.

QDTE has gained 23.52% over the past year, which is a respectable result for an income-oriented strategy. But that performance came during a period of generally rising tech stocks and elevated volatility. The fund’s architecture rewards exactly those conditions. What it does not do is protect investors when those conditions reverse. Anyone holding QDTE for income should understand that the weekly distribution is not a cushion against a serious drawdown in its underlying holdings. It is simply what the fund pays while it waits to see whether the landmine gets stepped on.
2026-03-05 19:06 6d ago
2026-03-05 13:51 6d ago
Mortgage refinance comeback: United Wholesale Mortgage's refi volume jumps 387% from cycle low stocknewsapi
UWMC
Want more housing market stories from Lance Lambert’s ResiClub in your inbox? Subscribe to the ResiClub newsletter.

After taking a big macro hit during the 2022 rate-shock, United Wholesale Mortgage’s (UWM) refinance volume has found its footing—and keeps climbing:

2020: $140B 2021: $139B 2022: $36B 2023: $14B (cycle low) 2024: $43B 2025: $70B That’s a +387% increase in UWM’s refi volume since its 2023 cycle low.

Even without a full refi boom, refinance volume is slowly coming back, with the average 30-year fixed mortgage rate as tracked by Freddie Mac down to 5.98% last week—or 1.81 bps below its cycle high of 7.79% in October 2023.

Many recent borrowers who took on higher mortgage rates (2023–2024 vintages) are jumping at the opportunity to refinance and secure some payment relief. At the same time, UWM’s purchase volume has remained relatively steady in the $90B–$96B range over the past few years.

The lack of a sharp decline in purchase volume following the rate-shock is impressive when you consider the macro picture: While U.S. existing home sales fell sharply in 2022, UWM’s purchase volume held steady as the wholesale channel gained share during the downturn. Many smaller lenders pulled back or exited, and brokers consolidated volume toward large, price-competitive players. UWM kept pushing forward. That purchase stability gives UWM a great base to operate from as refis improve.

While UWM’s refinance rebound is happening faster than most mortgage firms (and as a result, it’s taking refinance market share), refinance activity overall is slowly bouncing off the rate-shock lows.
2026-03-05 19:06 6d ago
2026-03-05 13:52 6d ago
Hanmi Issues 2025 Annual Shareholder Letter stocknewsapi
HAFC
March 05, 2026 13:52 ET  | Source: Hanmi Bank

LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today announced the release of its 2025 annual letter to shareholders entitled “Consistent Performance Through Strong Execution” authored by President and Chief Executive Officer Bonnie Lee. To view the letter please visit Hanmi Financial Corporation (HAFC).

About Hanmi Financial Corporation
Headquartered in Los Angeles, California, Hanmi Financial Corporation owns Hanmi Bank, which serves multi-ethnic communities through its network of 32 full-service branches, five loan production offices and three loan centers in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington, and Georgia. Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses. Additional information is available at www.hanmi.com.

Investor Contacts:
Romolo (Ron) Santarosa
Senior Executive Vice President & Chief Financial Officer
213-427-5636

Lisa Fortuna
Investor Relations
Financial Profiles, Inc.
[email protected]
310-622-8251

Source: Hanmi Bank
2026-03-05 19:06 6d ago
2026-03-05 13:54 6d ago
Horizon Technology Finance Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses stocknewsapi
HRZN
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Horizon Technology Finance Corporation (NASDAQ: HRZN). The investigation focuses on Horizon Technology Finance executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Horizon Technology Finance securities?

If you purchased Horizon Technology Finance securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation

On March 3, 2026, Horizon Technology Finance Corporation announced its fourth quarter and full year 2025 financial results. The Company reported net investment income of $0.18 per share for the fourth quarter of 2025, down from $0.32 per share in the third quarter of 2025. 

Following these disclosures, Horizon Technology Finance common stock fell approximately 23% over the next trading day.

In light of these disclosures, Johnson Fistel is investigating whether Horizon Technology Finance complied with the federal securities laws. If you suffered losses from your investment in Horizon Technology Finance stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements

In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected] 
2026-03-05 19:06 6d ago
2026-03-05 13:55 6d ago
Western Union Taps Solana Stablecoin Rails via Crossmint Deal stocknewsapi
WU
Key Takeaways Western Union partners Crossmint to launch USDPT stablecoin on Solana via its new Digital Asset Network.WU's network links stablecoins to 360,000 payout locations for local-cash pickup in 200 countries.WU sees blockchain settlements reducing intermediaries and delays, helping protect margins in remittances. The Western Union Company (WU - Free Report) is expanding its presence in the digital asset ecosystem through a partnership with Crossmint. The collaboration will support the launch of WU’s U.S. dollar-denominated stablecoin, USDPT, which will be issued on the Solana blockchain and integrated into the company’s newly introduced Digital Asset Network.

The initiative aims to bridge the gap between digital assets and real-world money movement. WU’s Digital Asset Network is designed to connect stablecoins with its extensive physical payout infrastructure, allowing users to convert digital dollars into local currency through over 360,000 collection locations worldwide. This network could make stablecoin transactions much more convenient for everyday cross-border transfers, particularly in areas where traditional banking options are hard to come by.

Under this partnership, Crossmint will integrate USDPT into its wallet and payment APIs, enabling fintech developers and enterprises to build applications that support instant transfers, stablecoin holdings and seamless connections to Western Union’s global payout network. Over time, this infrastructure could allow digital wallets and fintech platforms to move funds across borders almost instantly while still offering reliable cash pickup options in more than 200 countries.

Strategically, stablecoins could offer WU an opportunity to improve transaction efficiency and potentially lower the cost of cross-border settlements. Traditional remittance systems often get bogged down with multiple intermediaries, currency conversion fees and delays in settlement. By leveraging blockchain infrastructure, transfers can settle nearly instantly while maintaining a dollar-denominated value through the stablecoin. This approach could help Western Union safeguard its profit margins and stay competitive against fintech and crypto-based remittance services.

If adoption scales, USDPT could unlock new revenue streams tied to digital payments infrastructure while preserving Western Union’s powerful global payout network. In a payments market increasingly shaped by blockchain efficiency, integrating stablecoins might help the company defend its market share while gradually improving operating leverage through faster and cheaper settlement systems.

WU’s Price PerformanceOver the past year, WU shares have fallen 13.4% compared with the industry’s decline of 19.3%.

Image Source: Zacks Investment Research

WU’s Zacks Rank & Key PicksWU currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the business services space are Remitly Global, Inc. (RELY - Free Report) , Sezzle Inc. (SEZL - Free Report) and Dave Inc. (DAVE - Free Report) . While Remitly Global and Sezzle sport a Zacks Rank #1 (Strong Buy) each at present, Dave carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Remitly Global’s current-year earnings of 51 cents per share has remained stable over the past seven days. Remitly Global beat earnings estimates in three of the trailing four quarters. The consensus estimate for current-year revenues is pegged at $2 billion, implying 19.5% year-over-year growth.

The Zacks Consensus Estimate for Sezzle’s current-year earnings of $4.69 per share has witnessed four upward revisions in the past seven days against no movement in the opposite direction. Sezzle beat earnings estimates in each of the trailing four quarters, with the average surprise being 66.7%. The consensus estimate for current-year revenues is pegged at $576.9 million, implying 28.1% year-over-year growth.

The Zacks Consensus Estimate for DAVE’s current-year earnings of $14.07 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. Dave beat earnings estimates in each of the trailing four quarters, with the average surprise being 54.2%. The consensus estimate for current-year revenues is pegged at $692.5 million, implying 25% year-over-year growth.
2026-03-05 19:06 6d ago
2026-03-05 13:55 6d ago
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? stocknewsapi
BMY
Key Takeaways Reblozyl tops $2.3B annualized sales, driving Bristol Myers growth amid declining legacy drug revenues.BMY reports data showing Reblozyl improved hemoglobin and reduced transfusion burden in alpha-thalassemia.Competition is rising as Keros tests elritercept in Phase III and Geron's Rytelo gains traction in MDS anemia. Bristol Myers (BMY - Free Report) is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line growth amid a significant decline in legacy drug sales.

Among these, Reblozyl, the thalassemia drug that BMY co-developed with Merck, continues to be a major growth driver, with annualized sales now exceeding $2.3 billion.

Reblozyl is indicated for the treatment of anemia in adult patients with transfusion-dependent and non-transfusion-dependent beta thalassemia who require regular red blood cell (RBC) transfusions. It is also approved for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts (RS) and require RBC transfusions, as well as for adult patients with very low- to intermediate-risk MDS who are ESA-naïve and may require regular RBC transfusions, regardless of RS status.

Sales in the United States are being driven by strong demand in first-line RS-positive and RS-negative myelodysplastic syndrome-associated anemia. International sales growth is being driven by strong launches in new markets.

BMY expects continued strong growth opportunities, particularly in the RS-negative MDS indication.

Last month, BMY reported positive top-line results from an ongoing ex-U.S. Phase 2 registrational study evaluating Reblozyl for anemia in adults with alpha-thalassemia.

Both non-transfusion-dependent and transfusion-dependent patient cohorts met their primary endpoints. Reblozyl significantly increased hemoglobin levels in non-transfusion-dependent patients and reduced red blood cell transfusion burden in transfusion-dependent patients. The study also met all key secondary endpoints, with safety results consistent with the drug’s established profile.

The data will be presented at an upcoming medical meeting and discussed with China’s drug regulator.

Approval in additional geographies should further boost sales.

Competition for BMY’s ReblozylKeros Therapeutics (KROS - Free Report) , a clinical-stage biopharmaceutical company, is evaluating elritercept, in partnership with Takeda, for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and patients with myelofibrosis.

A phase III study, RENEW, is evaluating elritercept for the treatment of anemia and thrombocytopenia in patients with very low-, low-, or intermediate-risk MDS.

In July 2025, KROS announced that the first patient had been dosed in the RENEW study. This triggered a $10 million milestone payment to Keros under its global licensing agreement with Takeda.

Reblozyl also competes with established ESAs like Procrit (epoetin alfa), though it works through different mechanisms.

Geron Corporation’s (GERN - Free Report) Rytelo (imetelstat) is also approved for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.

Geron is witnessing strong uptake of Rytelo since its approval in June 2024. The drug generated $183.6 million in 2025. Geron expects Rytelo sales in the range of $220 million to $240 million in 2026.

BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 20.6% in the past year compared with the industry’s growth of 4.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock currently trades at 10.05x forward earnings, higher than its mean of 8.46x but lower than the large-cap pharma industry’s 18.22x.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 EPS has moved north to $6.26 from $6.08 in the past 30 days, while that for 2027 has moved up to $6.07 from $5.88, 

Image Source: Zacks Investment Research
2026-03-05 19:06 6d ago
2026-03-05 13:55 6d ago
Vermilion Energy: A Deep Value Natural Gas Play That's Still Too Cheap stocknewsapi
VET
2.44K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of VET either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2026-03-05 19:06 6d ago
2026-03-05 13:55 6d ago
Caterpillar Inc. (CAT) Discusses New Strategy and Leadership Transition in Construction Industries Transcript stocknewsapi
CAT
Caterpillar Inc. (CAT) Discusses New Strategy and Leadership Transition in Construction Industries March 5, 2026 11:00 AM EST

Company Participants

Alex Kapper - Vice President of Investor Relations
Rodney Shurman - Group President of Construction Industries
Joseph Creed - CEO & Director

Conference Call Participants

Stephen Volkmann - Jefferies LLC, Research Division

Presentation

Alex Kapper
Vice President of Investor Relations

All right. Good morning, everyone, and welcome to the Caterpillar fireside chat here at CONEXPO 2026. We're welcome to have you join us today live from Las Vegas. My name is Alex Kapper, Vice President of Investor Relations.

Just a few quick reminders before we get started. Today, we will make forward-looking statements which are subject to risks and uncertainties. For a full list of risks which may have a material impact on our actual results, please see our SEC filings, including the 10-K, which was filed just last month. We'll also refer to non-GAAP numbers. For any reconciliation to U.S. GAAP numbers, you can see our appendix of our latest earnings presentation. And lastly, we've done our safety briefing here in the room. So we just encourage anyone joining remotely to be aware of your surroundings and your local safety protocols.

So with that, I'll hand it over to our host, Steve Volkmann.

Stephen Volkmann
Jefferies LLC, Research Division

Thank you, Alex, and good morning, everybody. My welcome as well to this fireside chat. I'm Steve Volkmann with Jefferies, and very pleased to be hosting this event. So obviously, joining me here today are Joe Creed, Chairman and CEO; and Rod Shurman, who is the Group President of Construction Industries, I think, for 32 days now.

Rodney Shurman
Group President of Construction Industries

32, 33.

Stephen Volkmann
Jefferies LLC, Research Division

All right. So looking forward to, I think, your first fireside chat
2026-03-05 19:06 6d ago
2026-03-05 13:55 6d ago
Rigetti Computing, Inc. (RGTI) Q4 2025 Earnings Call Transcript stocknewsapi
RGTI
Q4: 2026-03-04 Earnings SummaryEPS of -$0.03 beats by $0.00

 |

Revenue of

$1.87M

(-17.85% Y/Y)

misses by $458.58K

Rigetti Computing, Inc. (RGTI) Q4 2025 Earnings Call March 4, 2026 5:00 PM EST

Company Participants

Subodh Kulkarni - CEO, President & Director
Jeffrey Bertelsen - Chief Financial Officer

Conference Call Participants

Kevin Garrigan - Jefferies LLC, Research Division
Troy Jensen - Cantor Fitzgerald & Co., Research Division
Quinn Bolton - Needham & Company, LLC, Research Division
David Williams
Sreekrishnan Sankarnarayanan - TD Cowen, Research Division
Craig Ellis - B. Riley Securities, Inc., Research Division
Tyler Perry Anderson - Craig-Hallum Capital Group LLC, Research Division
John McPeake - Rosenblatt Securities Inc., Research Division
Brian Kinstlinger - Alliance Global Partners, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Rigetti Computing Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. [Operator Instructions]. I would now like to hand the conference over to your speaker today, CEO, Dr. Subodh Kulkarni.

Subodh Kulkarni
CEO, President & Director

Good afternoon, everyone, and thank you for joining us for Rigetti's Fourth Quarter and Full Year 2025 Earnings Conference Call. I'm pleased to be joined today by our Chief Financial Officer, Jeff Bertelsen, who will walk you through our financial results in more detail following my overview. Also with us is our Chief Technology Officer, David Rivas, who will be available to participate in the Q&A session following our prepared remarks. We appreciate your continued interest in Rigetti, and we look forward to answering your questions at the conclusion of our remarks.

Before we begin, I would like to remind everyone that today's call along with our fourth quarter and full year 2025 press release contains forward-looking statements. These statements reflect our current expectations, objectives and underlying assumptions regarding our outlook and future operating results. These forward-looking statements are subject to a number of risks and uncertainties that could
2026-03-05 19:06 6d ago
2026-03-05 13:55 6d ago
Versant Media Group, Inc. (VSNT) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript stocknewsapi
VSNT
Versant Media Group, Inc. (VSNT) Morgan Stanley Technology, Media & Telecom Conference 2026 March 5, 2026 11:30 AM EST

Company Participants

Mark Lazarus - CEO & Director

Conference Call Participants

Thomas Yeh - Morgan Stanley, Research Division

Presentation

Unknown Analyst

All right. We're going to kick us off here on day 4 of the Morgan Stanley TMT Conference in San Francisco. We're really excited to have Mark Lazarus, the CEO of Versant, which spun off from Comcast in early January.

Quick disclosure. For important disclosures, please see the Morgan Stanley research disclosure website. And if you have any questions, please feel free to reach out to your Morgan Stanley sales rep. I'm joined by Thomas Yeh from the Morgan Stanley Media and Entertainment research team.

Mark, thanks so much for being here.

Mark Lazarus
CEO & Director

Thank you for having us.

Question-and-Answer Session

Unknown Analyst

So you just reported earnings and reiterated your outlook for 2026. What have been your biggest learnings in the first few months of operating as a stand-alone company following the separation from Comcast?

Mark Lazarus
CEO & Director

We've learned a lot. We learned that our -- I think that we really realized that while we have big iconic, well-known brands, they were really hidden inside of Comcast, and that's been a lot of the premise for the entirety of the spin that we can unlock value with these very popular big brands. So taking CNBC, MS NOW, Golf Channel, E!, Oxygen, SYFY, Fandango, GolfNow and really exposing them. And then bucketing them into vertical businesses where we can expand beyond the pay television ecosystem, that we've been so successful and are so successful in, but we'll be able to invest into them. We'll be able to do that, and I think the biggest learning is how important our strong balance sheet is, right?
2026-03-05 19:06 6d ago
2026-03-05 13:56 6d ago
Teads Holding Co. (TEAD) Q4 2025 Earnings Call Transcript stocknewsapi
TEAD
Teads Holding Co. (TEAD) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST

Company Participants

David Kostman - CEO & Director
Jason Kiviat - Chief Financial Officer

Conference Call Participants

Laura Martin - Needham & Company, LLC, Research Division
Matthew Condon - Citizens JMP Securities, LLC, Research Division
James Heaney - Jefferies LLC, Research Division
Zach Cummins - B. Riley Securities, Inc., Research Division

Presentation

Operator

Good day. Welcome to Teads' Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the call over to Teads Investor Relations. Please go ahead.

Unknown Executive

Good morning, and thank you for joining us on today's conference call to discuss Teads fourth quarter and full year 2025 results. Joining me on the call today, we have David Kostman and Jason Kiviat, the CEO and CFO of Teads.

During this conference call, management will make forward-looking statements based on current expectations and assumptions, including statements regarding our business outlook and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. These risk factors are discussed in detail in our annual report on Form 10-K for the year ended December 31, 2024, as updated in our subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the call's original date, and we do not undertake any duty to update any such statements. Today's presentation also includes references to non-GAAP financial measures. You should refer to the information contained in the company's fourth quarter and full year 2025 results announcement for definitional information and reconciliation of non-GAAP measures to the comparable GAAP financial measures. Our earnings release can be found on our IR website, investors.teads.com, under News and Events. With that, let me
2026-03-05 19:06 6d ago
2026-03-05 13:56 6d ago
Tecsys Inc. (TCS:CA) Q3 2026 Earnings Call Transcript stocknewsapi
TCS TCYSF
Tecsys Inc. (TCS:CA) Q3 2026 Earnings Call Transcript
2026-03-05 19:06 6d ago
2026-03-05 13:56 6d ago
Banco BBVA Argentina S.A. (BBAR) Q4 2025 Earnings Call Transcript stocknewsapi
BBAR
Banco BBVA Argentina S.A. (BBAR) Q4 2025 Earnings Call Transcript
2026-03-05 19:06 6d ago
2026-03-05 13:56 6d ago
Cresco Labs Inc. (CRLBF) Q4 2025 Earnings Call Transcript stocknewsapi
CRLBF
Cresco Labs Inc. (CRLBF) Q4 2025 Earnings Call Transcript
2026-03-05 19:06 6d ago
2026-03-05 13:57 6d ago
Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial stocknewsapi
RHHBY
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann Purchase Licensing Rights, opens new tab

March 5 (Reuters) - Genentech, ​part of Roche (ROG.S), opens new tab, said ‌on Thursday that its experimental obesity drug helped ​people lose up to ​10.7% of their body ⁠weight in a ​mid-stage study.

In the 493-patient trial, ​the drug, petrelintide, helped people lose up to 10.7% ​of their body ​weight over 42 weeks, far more ‌than ⁠the 1.7% seen with a placebo.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Roche gained access to petrelintide through ​a ​collaboration ⁠and licensing deal signed with Denmark's ​Zealand Pharma last ​year, ⁠giving the Swiss drugmaker shared development rights to ⁠the ​amylin‑based obesity ​therapy.

Reporting by Kamal Choudhury in Bengaluru; ​Editing by Alan Barona

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-03-05 19:06 6d ago
2026-03-05 13:58 6d ago
FIVA: International Value Equities Could Outperform US Indices In 2026 stocknewsapi
FIVA
Fidelity International Value Factor ETF (FIVA) offers low-cost, value-oriented international equity exposure, trading at a 14.19x P/E and yielding 2.52%. FIVA is positioned to benefit from ongoing investor rotation into value stocks and international diversification amid concerns over US growth and AI-driven market concentration. Recent share price declines, potentially driven by Middle East disruptions, present a potential buy opportunity as energy-related risks may be short-lived.
2026-03-05 19:06 6d ago
2026-03-05 13:59 6d ago
Diversified Energy TR-1 stocknewsapi
DEC
March 05, 2026 13:59 ET  | Source: Diversified Energy PLC

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISINUS25520W1071 Issuer Name Diversified Energy Company  UK or Non-UK Issuer Non-UK  2. Reason for Notification 

An acquisition or disposal of financial instruments  3. Details of person subject to the notification obligation 

NameBarclays PLC  City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom  4. Details of the shareholder 

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above   City of registered office (if applicable)   Country of registered office (if applicable)   5. Date on which the threshold was crossed or reached 

03-Mar-2026  6. Date on which Issuer notified 

05-Mar-2026  7. Total positions of person(s) subject to the notification obligation 

.% of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reachedBelow notifiable ThresholdBelow notifiable ThresholdBelow notifiable ThresholdBelow notifiable ThresholdPosition of previous notification (if applicable)2.4600002.8000005.260000 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares 

Class/Type of shares ISIN code(if possible)Number of direct voting rights (DTR5.1)Number of indirect voting rights (DTR5.2.1)% of direct voting rights (DTR5.1)% of indirect voting rights (DTR5.2.1)US25520W1071 Below notifiable Threshold Below notifiable ThresholdSub Total 8.ABelow notifiable ThresholdBelow notifiable Threshold
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrumentExpiration dateExercise/conversion periodNumber of voting rights that may be acquired if the instrument is exercised/converted% of voting rights     Sub Total 8.B1   
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights       Sub Total 8.B2   
9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling personName of controlled undertaking% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable thresholdBarclays PLCBarclays Bank PLC   Barclays PLCBarclays Capital Inc.   Barclays PLCBarclays Capital Securities Limited   
10. In case of proxy voting

Name of the proxy holder   The number and % of voting rights held   The date until which the voting rights will be held   11. Additional Information

Full chain of controlled undertaking:
Barclays PLC
Barclays Bank PLC (100%)
Barclays Capital Securities Limited (100%) Barclays PLC
Barclays Bank PLC (100%)
Barclays US Holdings Limited (100%)
Barclays US LLC (100%)
Barclays Group US Inc. (100%)
Barclays Capital Inc. (100%)

Trading book exemption applied

  12. Date of Completion 

05-Mar-2026   13. Place Of Completion 

London
2026-03-05 19:06 6d ago
2026-03-05 14:00 6d ago
FRMI FINAL DEADLINE ALERT: Fermi Inc. Facing Securities Class Action Over IPO And Subsequent Disclosures -- Hagens Berman stocknewsapi
FRMI
FRMI Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 6th Deadline

, /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in Fermi Inc. (NASDAQ: FRMI) regarding the March 6, 2026, lead plaintiff deadline in a pending securities class action against Fermi, certain of Fermi's top executives and directors, and underwriters of Fermi's Initial Public Offering (IPO).

CLICK HERE TO SUBMIT YOUR FRMI LOSSES

The litigation alleges that Fermi misrepresented the demand for its flagship "Project Matador"—a massive AI data center campus—and the stability of its primary anchor tenant. The complaint alleges that Defendants' misstatements were allegedly revealed on Dec. 12, 2025, when Fermi disclosed that the first tenant for its anticipated Project Matador AI campus had terminated its $150 million Advance in Aid of Construction Agreement (AICA), which would have supplied construction costs for the facility. On this news, the price of Fermi stock fell nearly 34%, according to the complaint.

Click here to visit Hagens Berman's FRMI Case Page
Click here to view Hagens Berman's video summarizing Hagens Berman's investigation.

"We are investigating whether Fermi's IPO materials painted an artificial picture of demand to secure financing from investors," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claims.

The Fermi Inc. (FRMI) Securities Class Action's Allegations: The Project Matador Illusion and Anchor Tenant Risk

The pending litigation alleges that Fermi and its executives issued misleading statements regarding the viability of its core infrastructure project:

Overstated Tenant Demand: The complaint alleges that Fermi's IPO registration statement inflated the actual demand for Project Matador's multi-gigawatt capacity to attract high-valuation multiples.
  Concealed Tenant Risks: The complaint alleges that Defendants misrepresented and omitted to disclose the extent to which Project Matador would rely on a single tenant's funding commitment to finance the construction of Project Matador, and that there was a significant risk that the tenant would terminate its funding commitment.
  The $150M AICA Termination: On Dec. 12, 2025, Fermi stunned the market by announcing that the First Tenant had terminated the AICA agreement after the exclusivity period expired. Following this announcement, Fermi's stock price plummeted 33.8% in a single day. By the commencement of the Fermi class action lawsuit, the price of Fermi stock has traded as low as $8.59 per share, a 59% decline from the $21.00 per share IPO price.
  Dual Pronged Class: The Fermi class action lawsuit seeks to represent purchasers or acquirers of Fermi Inc. (NASDAQ: FRMI): (i) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with Fermi's Oct. 2025 IPO; and/or (ii) securities between Oct. 1, 2025 and Dec. 11, 2025, inclusive (the "Class Period"). Next Steps: Contact Partner Reed Kathrein Today

Hagens Berman is a top-tier plaintiff litigation firm recognized for prosecuting complex securities fraud class actions.

Mr. Kathrein is actively advising investors who purchased FRMI shares pursuant and/or traceable to the October 2025 IPO, or on the open market between Oct. 1, 2025 – Dec. 11, 2025.

The Lead Plaintiff Deadline is March 6, 2026.

TO SUBMIT YOUR FERMI (FRMI) LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:

Click Here to Report Your FRMI Investment Losses to Hagens Berman Contact: Reed Kathrein at 844-916-0895 or email [email protected] Whistleblowers: Persons with non-public information regarding Fermi should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP
2026-03-05 19:06 6d ago
2026-03-05 14:00 6d ago
IBM and University Researchers Create a Never-Before-Seen Molecule and Prove its Exotic Nature with Quantum Computing stocknewsapi
IBM
- Published today in Science, the discovery marks the creation and observation of the first molecule with a half-Möbius electronic topology.
- It shows how quantum computers can directly contribute to understanding complex molecular behavior.

, /PRNewswire/ -- An international team of scientists from IBM (NYSE: IBM), The University of Manchester, Oxford University, ETH Zurich, EPFL and the University of Regensburg have created and characterized a molecule unlike any previously known — one whose electrons travel through its structure in a corkscrew-like pattern that fundamentally alters its chemical behavior. Published today in Science, it is the first experimental observation of a half-Möbius electronic topology in a single molecule.

Dyson orbital for electron attachment, calculated using quantum hardware. Credit: IBM and the University of Manchester

Left, a scanning tunneling microscopy image of the new half-Möbius molecule's electron orbital density; right, a simulated STM image of the molecule's orbital density, which was made using an IBM quantum computer. To the scientists' knowledge, a molecule with such topology has never before been synthesized, observed, or even formally predicted. Understanding this molecule's behavior at the electronic structure level required something equally fundamental: a high fidelity quantum computing simulation.

The discovery advances science on two fronts. For chemistry, it demonstrates that electronic topology — the property governing how electrons move through a molecule — can be deliberately engineered, not merely found in nature. For quantum computing, it is a concrete demonstration of a quantum simulation doing what it was designed to do: representing quantum mechanical behavior directly, at the molecular scale, to produce scientific insight that would otherwise have remained out of reach. 

"First, we designed a molecule we thought could be created, then we built it, and then we validated it and its exotic properties with a quantum computer," said Alessandro Curioni, IBM Fellow, Vice President, Europe and Africa, and Director of IBM Research Zurich. "This is a leap towards the dream laid out by renowned physicist Richard Feynman decades ago to build a computer that can best simulate quantum physics and a demonstration where, as he said, 'There's plenty of room at the bottom.' The success of this research signals a step towards this vision, opening the door for new ways to explore our world and the matter within it."

A Never-Before-Seen Molecule

The molecule, with the formula C₁₃Cl₂, was assembled atom-by-atom at IBM from a custom precursor synthesized at Oxford University, with individual atoms removed one at a time using precisely calibrated voltage pulses under ultra-high vacuum at near-absolute-zero temperatures.

Experiments with scanning tunneling and atomic force microscopy, both techniques pioneered at IBM, combined with quantum computing to reveal an electronic configuration with no counterpart in chemistry's existing record: an electronic structure that undergoes a 90-degree twist with each circuit, requiring four complete loops to return to the starting phase.

This half-Möbius topology is qualitatively distinct from any previously known molecule and can be reversibly switched between clockwise-twisted, counterclockwise-twisted and untwisted states — demonstrating that electronic topology is not a property to be discovered, but one that can now be deliberately engineered under specific conditions.

A Disruptive Scientific Tool: Quantum-Centric Supercomputing

The scientists in this experiment created a molecule that had never existed. Now they had to figure out why it worked, a task which challenged conventional computers. The electrons within C₁₃Cl₂ interact in deeply entangled ways — each influencing all the others simultaneously. Modeling that behavior requires tracking every possible configuration of those interactions at once, requiring computational demands that grow exponentially and can quickly overwhelm classical machines.

Quantum computers are different by nature because they operate according to the same quantum mechanical laws that govern electrons in molecules, and they can represent these systems directly rather than approximate them. They "speak" the same fundamental language as the matter they are built to study and that distinction, once largely theoretical, can now contribute to concrete scientific results.

This capability offers tremendous potential for quantum computers to support real-world experimentation with quantum-centric supercomputing workflows. By integrating quantum processing units (QPUs), CPUs, and GPUs, quantum-centric supercomputing allows complex problems to be broken into parts that are orchestrated and solved according to each system's strengths — achieving what no single compute paradigm can deliver alone.

Utilizing an IBM quantum computer within such a workflow, the team found helical molecular orbitals for electron attachment, a fingerprint of the half-Möbius topology. Moreover, simulation via quantum computing helped reveal the mechanism behind the formation of the unusual topology: a helical pseudo-Jahn-Teller effect.

This achievement builds on IBM's long legacy in nanoscale science. The scanning tunneling microscope (STM) was invented at IBM in 1981, for which IBM scientists Gerd Binnig and Heinrich Rohrer were awarded the Nobel Prize in 1986. Its creation enabled researchers to image surfaces atom by atom. In 1989, IBM scientists developed the first reliable method for manipulating individual atoms. Over the past decades, the IBM team has extended these techniques to build and control increasingly exotic molecular structures.

RESEARCHER QUOTES

Dr. Igor Rončević, paper co-author, Lecturer in Computational and Theoretical Chemistry at Manchester University:
"Chemistry and solid-state physics advance by finding new ways to control matter. In the second half of the 20th century, substituent effects were very popular. For example, researchers explored how the potency of a drug or the elasticity of a material changes if, for example, a methyl is replaced with chlorine. The turn of the century brought us spintronics, introducing electron spin as a new degree of freedom to play with, and transforming data storage. Today, our work shows that topology can also serve as a switchable degree of freedom, opening a new powerful route for controlling material properties.

"The non-trivial topology of this molecule, and the exotic behavior of many other systems, arises from interactions between their electrons. Simulating electrons with classical computers is very hard – a decade ago we could exactly model 16 electrons, and today we can go up to 18. Quantum computers are naturally well-suited for this problem because their building blocks – qubits – are quantum objects, which mirror electrons. Using IBM's quantum computer, we were able to explore 32 electrons. However, the most exciting part is this is just the start. Quantum hardware is advancing rapidly, and the future is quantum."

Dr. Harry Anderson, paper co-author, Professor of Chemistry at Oxford University:
"It is remarkable that the Lewis structure of C₁₃Cl₂ already indicates it is chiral, as confirmed by the experiment and quantum chemical calculations. It is also amazing that the enantiomers can be interconverted by applying voltage pulses from the probe tip."

Dr. Jascha Repp, paper co-author, Professor of Physics at the University of Regensburg:
"I'm really excited to be part of a project where quantum hardware does real science, not just demos. It's fascinating that a tiny molecule can have such a complex electronic structure that is challenging to simulate classically, and is so twisted and strange that it almost twists your mind."

For more about this research, please read the blog: Quantum simulates properties of the first-ever half-Möbius molecule, designed by IBM and researchers

About IBM

IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM's legendary commitment to trust, transparency, responsibility, inclusivity and service.

For more information, visit https://research.ibm.com.

Media Contact:

Erin Angelini
IBM Communications
[email protected]

Dave Mosher
IBM Research
[email protected]

SOURCE IBM
2026-03-05 19:06 6d ago
2026-03-05 14:00 6d ago
Nasdaq Texas Launches with Inaugural Dual Listings stocknewsapi
NDAQ
March 05, 2026 14:00 ET  | Source: Nasdaq, Inc.

Nasdaq Texas Celebrates Official Launch with the Nasdaq Stock Market Closing Bell at the Alamo with the First Cohort of Dual Listings

Nasdaq, Inc. to Dual List on Nasdaq Texas Alongside Inaugural Group

SAN ANTONIO, March 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq Texas will mark another milestone by ringing the Nasdaq Closing Bell at The Alamo, San Antonio, Texas, commemorating the 190th anniversary of the Battle of the Alamo and the full operational launch of Nasdaq Texas following approval of its listing rules from the U.S. Securities and Exchange Commission (SEC). This launch provides U.S. public companies with a Texas-based exchange designed to allow issuers to leverage the state’s business-friendly environment while maintaining access to Nasdaq’s suite of services and technology solutions.

The ceremony, which will be attended by Governor Greg Abbott and Lt. Governor Dan Patrick, celebrates several defining milestones: the official launch of Nasdaq Texas, the introduction of the first cohort of companies that will dual list on Nasdaq Texas and the announcement that Nasdaq, Inc. (Nasdaq: NDAQ) will dual list on Nasdaq Texas.

Held at one of Texas’ most historic landmarks, the event honors the state’s legacy of leadership and resilience while looking ahead to the future of modern capital markets.

A Foundational Commitment to Texas

Nasdaq Texas is now fully operational as a dual listing exchange and legally domiciled in the state. This milestone represents a long-term, structural commitment, aligning the exchange’s governance, operations, and strategy with Texas’ continued economic growth and leadership in capital formation.

Nasdaq Texas is designed to serve companies across sectors including technology, energy, industrials, life sciences, and financial services, providing access to deep liquidity, global investors, unparallelled market structure and technology solutions, all from a foundation rooted in Texas.

Introducing the First Cohort of Dual Listings

The first cohort of companies that are expected to dually list on Nasdaq Texas will join Nasdaq leadership to ring the Closing Bell at the Alamo. Together, they reflect the breadth and dynamism of Texas’ economy and help define the next era of capital formation in the state.

Participating companies include:

APA Corporation (Nasdaq: APA)Construction Partners Inc. (Nasdaq: ROAD)J.B. Hunt Transportation Services (Nasdaq: JBHT)Huntington Bancshares (Nasdaq: HBAN)ProFrac Services (Nasdaq: ACDC) In addition, Nasdaq, Inc. (Nasdaq: NDAQ) will dual list on Nasdaq Texas, underscoring its confidence in the platform and aligning the company with the same structure it offers issuers.

Executive Commentary

“The full launch of Nasdaq Texas represents a permanent, foundational commitment to the companies that want to build the future of the U.S. economy from this state,” said Rachel Racz, SVP and Head of Listings for Texas, Central and Southern U.S., and Latin America. “By being part of this community, Nasdaq is aligning itself with the leadership, resilience, and growth that define Texas. We are proud to welcome our first cohort of dual-listed companies and look forward to supporting them with the full strength and capabilities of Nasdaq Texas.”

“APA Corporation is proud to be part of the inaugural group of companies dual listing on Nasdaq Texas. This milestone reflects our deep roots in Texas and our continued commitment to disciplined capital allocation and long-term value creation for our shareholders,” said John J. Christmann IV, CEO of APA Corporation. “We are pleased to support the launch of Nasdaq Texas and to participate in this historic Closing Bell ceremony at the Alamo alongside fellow issuers.”

“As a lifelong Texan and long‑time builder of Sunbelt businesses, I’m proud to see a U.S. exchange designed to reflect Texas’ business‑friendly environment while leveraging Nasdaq’s world‑class technology and reach. At SunTx, we’re fortunate to partner with exceptional management teams like Construction Partners, a charter member of Nasdaq Texas. Under the leadership of Governor Greg Abbott and Lt. Governor Dan Patrick, Texas continues to set the pace for innovation, opportunity and enterprise, and we’re proud to help build on that momentum,” said Ned N. Fleming, III, Founder of SunTx Capital Partners and Executive Chairman of Construction Partners.

“Huntington Bancshares is proud to be among the first companies, and the first bank, to be listed on Nasdaq Texas, and we’re thrilled to take this next step with them,” said Steve Steinour, Chairman, President and CEO of Huntington Bancshares, Inc. “Texas represents growth, innovation and an entrepreneurial spirit that aligns perfectly with our purpose to make people’s lives better, help businesses thrive and strengthen the communities we serve.”

"J.B. Hunt is proud to be among the first companies to hold a dual listing with Nasdaq Texas. As the largest domestic intermodal and dedicated provider in North America and with significant scale in our Truckload, brokerage, and Final Mile businesses, we have deep roots in the region and support the full supply chain from the first mile to the last mile,” said Shelley Simpson, president and CEO of J.B. Hunt. “When our customers grow here, we grow here as well by investing in people, technology, and capacity to support their needs. This moment represents a meaningful opportunity, and we’re excited to align with the leadership driving economic growth across Texas. We look forward to what this means for the future of the U.S. economy and all that lies ahead.”

“It is an honor to represent ProFrac and my family at a celebration of Texas heritage. Our roots are here, our people are here, and we are proud to continue building companies that contribute to the strength and future of the Texas economy,” said  Matt Wilks, Executive Chairman, ProFrac Services.

Frequently Asked Questions

What is Nasdaq Texas?

Nasdaq Texas is a dual listing venue that expands Nasdaq’s presence in the state by providing companies with the ability to list on an exchange formed under Texas law while maintaining access to Nasdaq’s global platform, technology, and market infrastructure. It reflects Nasdaq’s long-term investment in Texas and its commitment to supporting capital formation across the region.

Who is Nasdaq Texas designed for?

Nasdaq Texas is designed for publicly traded companies that want to align with the Texas economy, operate within the state’s business-friendly governance environment, and maintain access to Nasdaq’s full suite of global capabilities, liquidity, and investor reach.

What are the benefits of dual listing on Nasdaq Texas?

Dually listing on Nasdaq Texas is a seamless process that allows companies to:

Align with Texas’ corporate governance framework and business environmentMaintain access to Nasdaq’s deep liquidity and global investor baseLeverage Nasdaq’s advanced market technologyIncrease visibility within one of the fastest-growing economic regions in the United States More information here: https://www.nasdaq.com/nasdaq-texas

About Nasdaq 
Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com. 

Nasdaq Media Contact 
Michelle Mendiola 
[email protected]  
+1 646 634 8350 

Cautionary Note Regarding Forward-Looking Statements: 
Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to the launch of the Nasdaq Texas exchange and the benefits to listing on Nasdaq Texas. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These factors include, but are not limited to, Nasdaq’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, geopolitical instability, government and industry regulation, interest rate risk, and U.S. and global competition. Further information on these and other factors are detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q, which are available on Nasdaq’s investor relations website at http://ir.nasdaq.com and the SEC’s website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

-NDAQG-  
2026-03-05 19:06 6d ago
2026-03-05 14:00 6d ago
Veeva Systems' Stock Up After Q4 Earnings & Revenues Beat Estimates stocknewsapi
VEEV
Key Takeaways Veeva Systems' Q4 FY26 EPS of $2.06 beat estimates and revenues rose 16% y/y to $836M.VEEV's subscription revenues climbed 16% to $707.7M, driven by demand for established and newer solutions.VEEV expects FY27 revenues of $3.59B and EPS around $8.85 while expanding AI agents across platforms. Veeva Systems, Inc. (VEEV - Free Report) reported adjusted earnings per share (EPS) of $2.06 for the fourth quarter of fiscal 2026, which increased 18.4% from the year-ago figure of $1.74. Adjusted EPS beat the Zacks Consensus Estimate by 7.3%.

GAAP EPS in the fiscal fourth quarter was $1.45, up 22.9% from the year-ago period’s $1.18.

VEEV’s Q4 Revenue DetailsIn the quarter under review, the company’s revenues totaled $836 million, beating the Zacks Consensus Estimate by 3.4%. On a year-over-year basis, the top line improved 16%.

Shares of the company gained 11.3% in yesterday’s after-market trading. The stock lost 31% in the past six months compared with the industry’s decline of 34.8%. However, the S&P 500 Index has increased 6.4% in the same time frame.

Image Source: Zacks Investment Research

The fiscal fourth-quarter top line was driven by Veeva Systems’ robust segmental performance.

VEEV’s FY26 ResultsFor fiscal 2026, VEEV registered total sales of $3.19 billion, up 16% year over year.

The company reported adjusted EPS of $8.10 for fiscal 2026, up 22.7% compared with fiscal 2025.

Segmental Analysis of VEEVVeeva Systems derives revenues from two operating segments: Subscription services, and Professional services and other.

In the fiscal fourth quarter, Subscription services revenues improved 16% from the year-ago quarter to $707.7 million. Per management, this uptick was driven by both its established and newer solutions.

Professional services and other revenues increased 14.1% year over year to $128.2 million.

Q4 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit improved 15.3% year over year to $622.5 million. The gross margin contracted 40 basis points (bps) to 74.5%.

Sales and marketing expenses increased 11.1% year over year to $110.2 million. Research and development (R&D) expenses rose 9.5% year over year to $198.8 million, while general and administrative expenses decreased 4.4% year over year to $67.6 million. Total operating expenses of $376.6 million increased 7.1% year over year.

Operating profit totaled $245.9 million, which increased 30.5% from the prior-year quarter. The operating margin in the fiscal fourth quarter expanded 330 bps to 29.4%.

VEEV’s Financial PositionThe company exited fourth-quarter fiscal 2026 with cash and cash equivalents and short-term investments of $6.56 billion compared with $6.64 billion at the fiscal third-quarter end.

Cumulative net cash provided by operating activities at the end of the quarter was $1.42 billion compared with $1.09 billion a year ago.

Q1 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the first quarter and full-year fiscal 2027.

For the fiscal first quarter, the company expects total revenues between $855 million and $858 million. The Zacks Consensus Estimate is currently pegged at $845.4 million.

Subscription revenues are estimated to be approximately $720 million, and the same for Professional services and other is expected to be in the range of $135-$138 million for the fiscal first quarter.

For the fiscal first quarter, adjusted EPS is anticipated between $2.13 and $2.14. The Zacks Consensus Estimate is pegged at $2.03.

Veeva Systems expects revenues for fiscal 2027 between $3,585 million and $3,600 million. The Zacks Consensus Estimate is currently pegged at $3.54 billion.

For fiscal 2027, Subscription revenues are expected to be approximately $3,040 million. This consists of Commercial Solutions’ subscription revenues of around $1,380 million and R&D Solutions’ subscription revenues of approximately $1,660 million.

Professional services and other revenues for fiscal 2027 are expected to be between $545 million and $560 million.

Adjusted EPS for fiscal 2027 is expected to be approximately $8.85. The Zacks Consensus Estimate is pegged at $8.50.

Our Take on Veeva Systems’ Q4 ResultsVeeva Systems exited the fourth quarter of fiscal 2026 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well.

Veeva Systems closed fiscal 2026 with strong momentum, delivering fourth-quarter results ahead of expectations marked by deepening partnerships and expansion with both new and existing customers. The company ended the year with a total of 1,552 customers, including 1,196 in Veeva R&D and Quality Solutions and 767 in Veeva Commercial Solutions. Strong customer success and product innovation helped VEEV achieve a $3 billion revenue run rate in early 2025. Looking forward, solid business momentum and continued operational discipline reinforce management’s confidence in achieving the company’s $6 billion revenue run-rate objective by 2030.

During the quarter, VEEV built deeply integrated, industry-specific AI capabilities across its platforms. With core systems of record embedded in critical life sciences workflows, the company believes it is uniquely positioned to deliver high-value AI that combines specialized datasets, sophisticated logic, deep process integration and safeguards while maintaining compliance and strong data integrity. Following the December launch of its first Veeva AI Agents supporting CRM and commercial content, several customers have gone live, while additional projects are underway. Management noted that more AI agents across its key application areas remain on track for release throughout 2026.

Veeva Development Cloud and Quality Cloud secured several top-20 biopharma wins during the quarter, including a major selection of Veeva RTSM as an enterprise standard. Safety momentum continued to gain traction with the sixth top-20 customer win and the first top-20 biopharma going live on Workbench and Signal. Veeva LIMS advanced toward its first top-20 biopharma go-live across two manufacturing sites expected in 2026.

The company continued to expand the adoption of its next-generation Vault CRM. More than 125 customers are now live, including two top-20 biopharmas across major markets, while 10 of the top-20 global biopharma companies have already committed to the platform. Management expects this number to rise by advancing its commercial strategy. Crossix also delivered strong momentum during the year across its Measurement and Audience solutions, further strengthening Veeva Systems’ commercial data and analytics capabilities.

VEEV’s Zacks Rank & Stocks to ConsiderVEEV carries a Zacks Rank #4 (Sell) at present.

Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , AngioDynamics (ANGO - Free Report) and Phibro Animal Health (PAHC - Free Report) .

Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.

AngioDynamics, sporting a Zacks Rank #1 at present, reported breakeven adjusted EPS for second-quarter fiscal 2026, surpassing the Zacks Consensus Estimate by 100%. Revenues of $79.4 million topped the Zacks Consensus Estimate by 4.5%.

ANGO has an estimated earnings growth rate of 59.3% for 2027 compared with the industry’s 17.1% rise. ANGO’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 82.1%.

Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
2026-03-05 19:06 6d ago
2026-03-05 14:05 6d ago
The Trade Desk Is Up 23.7% and the Debate Is Just Starting stocknewsapi
TTD
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Summit Art Creations / Shutterstock.com

When it comes to putting money where your mouth is, Jeff Green has put ~$148 million of his own money into The Trade Desk (NASDAQ:TTD) as a personal share purchase. Shares are up 24.43% over the past week, trading at $29.83 as of March 5, 2026. Reddit sentiment on TTD has climbed to 62 out of 100 (Bullish), up from 59 in the early morning hours. The catalyst is real, but the structural questions have not gone away.

The CEO Bet That Has r/stocks Talking The dominant thread driving TTD discussion comes from r/stocks, where user Tachiiderp posted about Green’s purchase:

The Trade Desk CEO Jeff Green bought $148 million worth of shares in the last 2 days
by u/Tachiiderp in stocks “Insider buys usually mark a bottom, but when several CEOs are doing it, is it a sign of desperation?” The post had accumulated 434 upvotes and 79 comments by noon ET. The community is split on what the signal means. TTD is down 55.48% over the past year and 21.96% year-to-date. Three reasons retail investors remain cautiously optimistic:

Q4 2025 EPS came in at $0.59 against a $0.50 estimate, and adjusted EBITDA margin reached 47%, the highest in recent quarters, demonstrating real operating leverage Q1 2026 revenue guidance of $678 million implies only 10.1% year-over-year growth, a sharp deceleration from 14.27% in Q4 and 25% in Q1 2025 , citing AI scale deficits and structural disadvantages versus walled gardens like Google and Meta Morningstar cut its fair value estimate from $60 to $35, citing AI scale deficits and structural disadvantages versus walled gardens like Google and Meta The Trade Desk’s OpenAI Angle Deserves Scrutiny Reports that The Trade Desk is in early discussions with OpenAI to manage advertising sales for its platforms have added fuel to the rally. Green’s argument is that TTD’s lack of owned inventory makes it the right partner in an AI-mediated advertising world. “The complexity of the global advertising market is not a weakness for The Trade Desk. It is a moat,” he said on the Q4 earnings call. The OpenAI discussions remain unconfirmed, and CPG and auto verticals, which represent over a quarter of TTD’s business, continued to weaken into Q1 2026.

Supply-side peer Magnite (NASDAQ:MGNI) posted net income growth of 535% with a $200 million buyback last week, suggesting real tailwinds across ad tech. Whether The Trade Desk can convert its open-internet thesis into reaccelerating revenue is the question heading into Q1 results.

Data Sources

Reddit sentiment and post data sourced from Fuse API proprietary Reddit sentiment tracking (February 14 to March 5, 2026) Earnings data and CEO quotes from The Trade Desk Q4 2025 earnings call transcript and SEC 8-K filing (February 25, 2026) News sentiment and analyst commentary from Alpha Vantage News Sentiment API, including Morningstar, Benzinga, and Sahm Capital coverage Price performance data from prior 247 Wall St. coverage and Fuse API price performance endpoint
2026-03-05 19:06 6d ago
2026-03-05 14:05 6d ago
Target Will Invest $6 Billion To Fix What It Broke stocknewsapi
TGT
NEW YORK, NEW YORK - DECEMBER 08: A view of the interior as Target opens "Target SoHo" - a design-forward shoppable concept store in SoHo, New York on December 08, 2025 in New York City. (Photo by Ilya S. Savenok/Getty Images for Target)

Getty Images for Target

Target just released another dismal earnings report, then leadership took to the stage for its annual Community Meeting to outline plans for a 2026 turnaround. What followed sounded awfully familiar—more promises of change, only this time it’s going to cost more to fix what ails the struggling retailer.

Nonetheless, investors bought into the narrative. Stock prices have climbed over 6% since the beginning of the week, currently trading around $120 per share, up from about $113. Investors are betting that new CEO Michael Fiddelke can spark a revival that his predecessor, Brian Cornell, couldn’t over the past couple of years.

The company expects net sales growth in the 2% range during 2026, with a small increase in comparable sales. Target plans to invest $5 billion in capital —$1 billion more than announced in November— to open 30 new stores and remodel 130+ stores. Over $1 billion of the capital investment will fund food and beverage expansion. It will also reset beauty and baby departments, reinvent home and pivot toward wellness. In addition, $1 billion in operational investment will be directed toward increased store staffing and training, brand marketing, and new technologies, including AI.

On the surface, the plan sounds promising and doable. Fiddelke responded that the company is playing the long game and reiterated the company’s North Star remains knowing exactly who Target is, adding, “We’re gonna come back to knowing who we are in the years to come.”

That last statement leaves a bigger question that the two-hour presentation didn’t answer: How did Target lose sight of its North Star in the first place? And can the new plan—that sounds a lot like the old plan—pull the company out of the hole that it has dug over the last few years?

MORE FOR YOU

GlobalData’s managing director, Neil Saunders, gives Target’s leadership team an A for effort, but stresses that the problems Target faces today are longstanding and little has been done to fix them.

“The hesitation comes not from whether these things are right—after all, they fix many of the things customers have been complaining about for years—it comes from whether Target can execute. Target’s track record has been poor,” he shared.

Fourth Quarter And Year End 2025In opening the fourth quarter and full year fiscal 2025 earnings report, the company congratulated itself for delivering results “in line with company expectations,” which, to be frank, were uninspiring.

Fourth quarter net sales were off 1.5% to $30.5 billion and the year ended on January 31 with sales down 1.7% to $104.8 billion. Operating income for the year dropped 8.1% to $5.1 billion and net earnings declined 9.4% to $4.8 billion.

While the company reported sales picked up in January and in February to start fiscal 2026—“serving as an important milestone on our path back to growth this year,” Fiddelke said in a statement— same-store-sales (SSS) declined 3.9% in fourth quarter, though comparable digital sales ticked up 1.9%, to bring overall comparable sales off by 2.5%.

It was an exceedingly poor showing for the holiday season after the company did so much to bolster sales, including price reductions on 3,000 food, beverage and essential items, activating an AI-powered gift finder and personal shopping assistant, integrating ChatGPT into the Target app and extreme Black Friday and Cyber Monday deals.

“There is no way to sugarcoat it: Target underperformed over the holiday quarter,” Saunders stated. “While expected, this continues a long-established pattern: in a tough trading environment, Target is struggling to show up for customers in a consistent and compelling way. There are too many out of stocks, too little inspiration in ranges, too much muddle and mess in stores.”

Habits Are Hard To BreakThese are going to be hard patterns to break, even with the renewed energy and commitment from Target leadership. One problem is that the people now promising change were in key positions when the bad patterns got started. CEO Feddelke has been with the company for over 20 years and chief merchandising officer Cara Sylvester, chief stores officer Adrienne Costanzo and chief operating officer Lisa Roath for nearly as long.

When Mike Baker, D.A. Davidson analyst, asked the obvious question—“One criticism may be that it’s the same management team. It’s the same faces, new strategies. What happened to all of a sudden realize we need to do something different?”—Feddelke was ready, saying that over half his leadership team is either in a new role or new to Target in the last 18 months.

He also stressed the value of his team’s long tenure and grounding in the corporate culture and said the team has candidly assessed where the company has been and what needs to change to move forward.

However, the challenges Target faces in the current moment didn’t happen overnight. These 20-year veterans were there when the company began its slide. And the leader who oversaw Target’s recent fall from grace, Brian Cornell, sits in the executive chair of the board.

Three-Year LookbackImmediately after the Covid pandemic, Target enjoyed two years of dynamic growth— advancing from $94 billion in 2020 to $106 billion in 2021 and $109 billion in 2022. But then, it started to flounder.

Over the three-year period between 2023 and 2025, net sales dropped 2.4%—not huge by bad enough. Worse, operating income and net earnings declined by about 10%. Diluted earnings per share slipped 9%, from $8.94 to $8.13.

Target net sales, operating income, net earnings 2023-2025

Table by Pamela Danziger from Target earnings reports

And over those three years, it opened nearly 50 new stores—starting fiscal 2023 with 1,948 stores and ending 2025 with 1,995. This challenges the assumption that 30 new stores this year will make a significant difference in sales. Seven of the 30 new stores will open this March.

Even more telling was comparable sales performance. Annual comparable sales slipped 4% in 2023, was basically flat in 2024 and dropped nearly 3% in 2025. Here’s a quarter-by-quarter replay.

Target quarterly net sales and comp sales change 2023-2025

Table by Pamela Danziger from Target earnings reports

Target MisstepsTarget’s missteps played a major role in its fall from 2023 to 2025. In 2023, its June Pride Month display caused outrage among more conservative customers, and when the company pulled Pride merchandise from some stores, it triggered a backlash from the other side.

Target managed to make amends with both constituencies in 2024, but it was the calm before the storm. In early 2025, the company’s decision to roll back its DEI program reignited customer anger, prompting widespread calls for boycotts and frustration among many Target employees who felt the decision was not aligned with corporate values.

Even after a year, concerns about the DEI decision persist. Reuters reported that a group of 27 investors just asked the company to reconsider the change.

“We are concerned that a series of recent public-facing decisions and communications by the company may have introduced reputational, operational and financial risks at a moment when Target is already navigating a challenging competitive and macroeconomic environment,” they wrote in a letter to the board and executive leadership.

Target did not address the DEI issue in its latest Community Meeting. However, Feddelke talked to the company’s philanthropic efforts, including a $1 million donation to its Bullseye Builds community project, one million staff volunteer hours devoted to local communities and its longstanding commitment to give 5% of profits to communities through products, cash and the Target Foundation.

Turning The PageFiddelke presented Target’s turnaround as a “new chapter of growth,” defined by four priorities for growth:

Merchandising authority through trendsetting, culturally relevant assortments that lead in style, design and value.Elevated guest experience across digital discovery and in-store experiences.Accelerated technology for greater efficiency, speed and more personalized customer engagement.Stronger teams and communities through investments in staff training, career growth and ongoing philanthropic efforts.There’s nothing to argue with in that plan—it’s all retail 101 and core to Target’s brand identity. The issue is whether the company has finally turned the page.

“We’ve heard some of this before so I’m skeptical whether this is going to be effective,” observed retail analyst Warren Shoulberg.

“The crazy part is that Wall Street has bought into these promises that things are going to get better when they’ve been saying it for the last eight quarters. Even with a new guy in there, I think Wall Street needs to be far more skeptical of whether this is actually going to work,” he concluded.

See also:

ForbesHow Target Will Restore Its ‘Tarzhay’ Image And Grow Sales By $15 Billion By 2030By Pamela N. DanzigerForbesTarget Withstood DEI Boycotts To Show Signs Of Reputation RecoveryBy Pamela N. DanzigerForbesAre Target Boycotts Starting To Take Their Toll?By Pamela N. Danziger
2026-03-05 19:06 6d ago
2026-03-05 14:05 6d ago
Lyft Is Down 79% and Reddit Is Asking If Bankruptcy Is Next stocknewsapi
LYFT
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Still a giant in the transportation space, Lyft (NASDAQ:LYFT) is trading at $13.32 as of March 5, 2026, down 31.2% year-to-date and off sharply from the $20.62 price at the time of Q3 2025 earnings. That collapse frames the central tension: Q4 2025 results showed genuine operational momentum, yet retail investors on Reddit are asking whether the company can survive. Social sentiment scores across a 24-hour window ending March 5 ranged from 20 to 32, firmly bearish, concentrated in r/investing.

Ultimately, for LYFT, Q4 tells two stories, depending on which line you read: gross bookings hit $5.07 billion, up 19% year-over-year, and active riders reached a record 29.2 million, up 18%. Adjusted EBITDA grew 37% year-over-year to $154.1 million. Full-year free cash flow exceeded $1.1 billion, an all-time high. But reported revenue of $1.592 billion missed the $1.649 billion consensus estimate, missed the $168 million headwind from legal, tax, and regulatory reserve changes consensus estimate, and was dragged down by a $2.755 billion, and the headline net income of $2.9 billion non-cash tax valuation allowance release was inflated by a $2.9B non-cash tax valuation allowance release.

Reddit’s Verdict Is Blunt The dominant thread on r/investing poses a stark question. User MainBuddy604 wrote:

Any investors in Lyft? Lyft stock has been abysmal since it’s IPO and has done worse than NYC taxi medallions have from the peak. Odd of Lyft going bankrupt?
by u/MainBuddy604 in investing The post, which drew 31 upvotes and 16 comments, frames Lyft as a “bloated and poorly run cab operation” and compares its stock decline to the collapse of NYC taxi medallions. The price data gives it grounding: Lyft shares are down 79.34% over five years. Three concrete pillars drive the bearish case:

This infographic provides an investment snapshot for Lyft, showing a bearish social sentiment score between 20-32 on Reddit, driven by abysmal stock performance, profitability concerns, and driver dissatisfaction as of early March 2026. Operating income for 2025 remained negative at -$188.4 million, indicating GAAP profitability remains elusive despite EBITDA progress. Multiple analysts cut price targets after Q4, with Mizuho dropping to $16 from $27, Susquehanna to $15 from $24, and BofA to $17 from $19. Driver protests over platform oversaturation and ongoing safety incidents create regulatory exposure that could pressure already-thin margins. Lyft’s AV Bet vs. Uber’s Narrative Dominance CEO David Risher declared that “2026 will be the year of the AV with deployments in the U.S. and overseas.” Lyft has a Waymo partnership in Nashville and a memorandum of understanding with Hamburg for Level 4 AV integration, though analysts note these are unlikely to drive near-term revenue catalysts. Uber (NASDAQ:UBER | UBER Price Prediction)’s Q3 2025 earnings call discussed autonomous vehicles and its own Waymo partnership at length, while Lyft went unmentioned, suggesting Lyft is reacting rather than leading.

The Test Ahead As far as analyst considerations go, RBC Capital’s Brad Erickson maintained a Buy with a $22 price target, citing operational momentum and Q1 2026 guidance calls for gross bookings of $4.86 billion to $5.00 billion and adjusted EBITDA of $120 million to $140 million. Whether Lyft hits those numbers without another large legal reserve charge is the cleanest test of whether this profitability inflection is structural or a one-off.
2026-03-05 18:06 6d ago
2026-03-05 12:00 6d ago
Mantle's stablecoin surges 75% in 30 days as liquidity flywheel kicks in cryptonews
MNT
Mantle’s ecosystem stablecoin has added roughly 375 million dollars in market value over the past month, climbing from about 494 million to nearly 870 million and cementing the network’s push to become a full‑stack on‑chain liquidity and banking layer built around ETH staking and restaking primitives.

Summary

Stablecoin market cap jumps 75% in 30 days, approaching 870 million dollars as Mantle’s liquidity products gain traction across DeFi. Growth rides on Mantle’s mETH staking and cmETH restaking stack, which channels yield and demand back into the broader ecosystem. Mantle’s deep treasury and “fortress” balance sheet reinforce confidence in its stablecoin and DeFi rails despite wider market volatility.
Mantle’s stablecoin engine is firing on all cylinders. Over the past 30 days, the total market value of the Mantle ecosystem stablecoin has risen from roughly 494 million dollars to around 870 million, a gain of more than 75% that sharply outperforms the broader market and highlights the chain’s emerging role as an on‑chain liquidity hub.

The move comes as Mantle doubles down on an integrated strategy: pair an Ethereum Layer 2 with native liquid staking and restaking, then plug that liquidity into DeFi. At the base layer sits mETH, Mantle’s liquid staking token for Ethereum, which has already attracted more than 1 billion dollars in total value locked by letting users earn staking rewards while keeping their assets liquid. On top of that, cmETH extends those positions into restaking, unlocking additional yield and incentives without forcing users to unwind core ETH exposure.

This composable stack is now bleeding directly into stablecoin demand. As traders and protocols seek dollar liquidity backed by yield‑bearing collateral, Mantle’s stablecoin becomes a natural settlement and liquidity layer inside the ecosystem, tightening the feedback loop between ETH staking flows, DeFi usage and dollar‑denominated volume. Campaigns such as “Methamorphosis” and ecosystem incentive seasons have further accelerated user onboarding and capital rotation into Mantle’s products.

Underpinning the growth is a balance sheet that rivals mid‑tier centralized players. Mantle controls a multi‑billion‑dollar treasury, including more than 270,000 ETH, giving the DAO ample capacity to backstop liquidity, co‑invest in protocols and defend key pegs or markets when needed. Research firms have already labeled Mantle a “fortress” protocol for its ability to withstand severe price shocks in its native token while maintaining solvency. If current growth persists, Mantle’s stablecoin could become one of the core dollar rails for restaking‑centric DeFi over the coming cycle.
2026-03-05 18:06 6d ago
2026-03-05 12:00 6d ago
XRP ETF Race: Bitwise Says It's Now America's Largest cryptonews
XRP
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitwise CEO Hunter Horsley says the firm’s XRP spot ETF has moved into the top slot in the US market, edging out rivals on assets as the category’s liquidity and asset base continue to expand.

“The Bitwise XRP ETF (ticker: XRP) is now the largest XRP ETF in America. $10,000,000 inflows so far this week. Grateful to investors entrusting Bitwise to steward their assets,” Horsley wrote on X.

The Bitwise XRP ETF (ticker $XRP ) is now the largest XRP ETF in America.

$10,000,000 inflows so far this week.

Grateful to investors entrusting @Bitwise to steward their assets.

Onward — https://t.co/b9OENfcreD

— Hunter Horsley (@HHorsley) March 4, 2026

XRP ETF Market: By The Numbers SoSoValue’s US XRP spot ETF dashboard shows Bitwise’s fund at $289.00 million in net assets. That places it just ahead of Canary’s XRPC at $285.79 million, a gap of roughly $3.21 million, or about 0.3% of the category’s $1.08 billion total.

The rest of the pack sits a tier below the leaders. Franklin’s XRPZ shows $247.27 million in net assets, 21Shares’ TOXR has $179.34 million, and Grayscale’s GXRP stands at $78.18 million. On the fee front, SoSoValue lists XRP at 0.34%, XRPC at 0.50%, XRPZ at 0.19%, TOXR at 0.30%, and GXRP at 0.35%.

Category-level flow data shows the group took in $4.19 million of net inflows on March 4, pushing cumulative net inflows to $1.26 billion. Trading activity also picked up yesterday: total value traded hit $56.03 million that session, while aggregate net assets rose to $1.0796 billion — about 1.21% of XRP’s market cap.

Meanwhile, the flow history paints a very front-loaded launch. From Nov. 13, 2025 through March 4, 2026, the category logged 62 sessions with net inflows, versus six outflow sessions (with another six flat days).

The single biggest creation day was Nov. 14 with $243.05 million of net inflows; the largest redemption day came much later on Jan. 29, when the group posted -$92.92 million.

That early surge matters because it still dominates the tape: roughly 77% of the $1.26 billion cumulative net inflow in your file arrived within the first four weeks after inception, and average daily net inflows fell sharply after that initial ramp (about $48.5 million/day over the first ~20 sessions versus ~$5.3 million/day in subsequent sessions).

Weekly aggregates tell the same story: the first month repeatedly printed nine-figure weeks, including the strongest week starting Nov. 24 at roughly $243.95 million net inflow. By contrast, the most recent four weeks average single-digit millions per week, and there were two net-outflow weeks overall — with the worst week starting Jan. 26 at about -$52.26 million.

Put differently, the “Bitwise is now the largest” milestone is happening in a market that appears to have moved from launch-phase allocation to maintenance-phase churn, where rankings can flip on marginal flow differences and NAV moves.

At press time, XRP traded at $1.42.

XRP rises back above the 200-week EMA, 1-week chart | Source: XRPUSDT on TradingView.com Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

Jake Simmons has been a Bitcoin enthusiast since 2016. Ever since he heard about Bitcoin, he has been studying the topic every day and trying to share his knowledge with others. His goal is to contribute to Bitcoin's financial revolution, which will replace the fiat money system. Besides BTC and crypto, Jake studied Business Informatics at a university. After graduation in 2017, he has been working in the blockchain and crypto sector. You can follow Jake on Twitter at @realJakeSimmons.
2026-03-05 18:06 6d ago
2026-03-05 12:00 6d ago
Can ASTER's $1.4M whale rotation spark a $0.80 breakout? cryptonews
ASTER
A prominent whale wallet sold 650 Ethereum [ETH] worth $1.4 million and redirected the capital into Aster [ASTER] purchases, raising attention across the market. 

On-chain tracking shows the address swapped the funds into 1.88 million ASTER worth roughly $1.4 million, indicating a deliberate capital rotation rather than random trading activity. This move follows a sequence of transfers recorded on-chain within the same timeframe. 

As a result, the whale now controls 4.45 million ASTER valued at nearly $3.18 million, placing the address among notable holders. Such repositioning often reflects shifting conviction between assets. 

In this case, the whale reduced exposure to ETH while expanding ASTER holdings significantly. As a result, the transaction introduces a strong accumulation narrative.

Inverse pattern forms near the key neckline At press time, ASTER was trading near $0.72, with the daily chart showing a developing inverse head‑and‑shoulders pattern in its price structure.

The left shoulder formed near $0.68, followed by a deeper decline toward $0.50, which established the head. Soon after, the price recovered and formed the right shoulder near $0.68, reinforcing the structure. 

Notably, ASTER traded just beneath the neckline resistance between $0.72 and $0.80. This region has repeatedly rejected upside attempts. 

However, price stabilization within this zone suggests growing buying pressure. Support levels remain clearly defined at $0.68 and $0.60, which previously halted declines. 

Since this pattern typically signals reversal conditions, traders now focus on the neckline zone. A sustained push above $0.80 could strengthen the broader recovery narrative.

Source: TradingView

Momentum indicators now reveal improving buyer activity after months of pressure. The Relative Strength Index sat near 56.85, while its Moving Average tracked close to 54.93. 

This shift places RSI above the neutral 50 threshold, which often signals strengthening market participation. Earlier in the downtrend, the indicator repeatedly struggled below the midline. 

However, recent recovery shows improving demand as ASTER stabilizes near resistance. In addition, the RSI trend now slopes upward, which reflects strengthening market conviction. 

Buyers appear increasingly willing to defend higher price zones. As a result, the indicator supports the developing reversal structure visible on the price chart. 

ASTER exchange flows hint at accumulation shifts Spot exchange activity now reveals shifting supply dynamics surrounding ASTER. Historical data shows several periods of large negative netflows, which indicate tokens leaving exchanges. 

Such outflows often suggest accumulation as investors move assets into private wallets. Notably, the latest reading shows a netflow near -$300.81K, which reflects a relatively balanced short-term environment. 

Selling pressure, therefore, appears limited at the moment. At the same time, the absence of large inflows reduces immediate distribution risk. 

Combined with the whale accumulation observed earlier, these flows support the idea that some investors continue positioning quietly. 

Source: CoinGlass

Derivatives traders lean strongly long on ASTER Derivatives positioning as of writing revealed a strong bullish tilt among experienced traders. Data from Binance showed 62.96% of accounts were positioned long, while 37.04% remained short.

This distribution produced a 1.70 Long/Short Ratio, indicating that bullish bets dominate. The ratio has gradually recovered after a brief drop earlier in the week. 

As a result, sentiment among top traders increasingly favors upside positioning. When professional traders maintain long exposure during consolidation, markets often anticipate volatility expansion. 

However, traders also monitor leverage concentration closely because aggressive positioning can amplify liquidations. 

Even so, the current bias clearly favors buyers. Combined with whale accumulation and improving technical structure, derivatives sentiment now aligns with the broader recovery narrative surrounding ASTER.

Source: CoinGlass

Conclusively, ASTER now sits at a critical inflection point as whale accumulation, improving technical structure, and bullish derivatives positioning converge simultaneously.

 The developing inverse head and shoulders pattern places $0.80 resistance at the center of attention.

If buyers sustain pressure above this zone, ASTER could extend recovery toward higher resistance levels. 

However, failure to break the neckline may prolong consolidation near $0.72. Traders, therefore, watch whether demand continues strengthening around current levels.

Final Summary Whale capital rotation into ASTER suggests growing conviction as traders quietly reposition ahead of potential structural breakout opportunities. Technical structure now aligns with improving sentiment, placing ASTER near a pivotal zone where demand could accelerate rapidly.